Antibody or antigen-binding fragment thereof, antibody-drug conjugate, and use thereof
By developing an anti-SEZ6 antibody conjugated with a cytotoxic substance to form an antibody-drug conjugate, the problem of the lack of effective treatment options for small cell lung cancer has been solved. This has enabled highly efficient targeted delivery and killing of small cell lung cancer, with excellent in vitro cytotoxicity and in vivo tumor inhibition effects.
Patent Information
- Application Number
- PCT/CN2024/091754
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-08
- Filing Date
- 2024-05-08
- Publication Date
- 2024-11-14
AI Technical Summary
There is a lack of effective treatment options for small cell lung cancer after first-line therapy, and existing antibody-drug conjugates have shortcomings in targeting and safety, making it difficult to effectively kill tumor cells.
An anti-SEZ6 antibody or its antigen-binding fragment was developed. By conjugating it with a cytotoxic substance, eczema analogue, an antibody-drug conjugate was formed. Taking advantage of the high expression of SEZ6 in small cell lung cancer, precise targeted delivery and killing of tumors were achieved.
It achieves highly efficient targeted delivery and killing of small cell lung cancer, demonstrating excellent in vitro cytotoxicity and in vivo tumor inhibition effects, and possesses excellent pharmacokinetic parameters.
Smart Images

Figure PCTCN2024091754-FTAPPB-I100001 
Figure PCTCN2024091754-FTAPPB-I100002 
Figure PCTCN2024091754-FTAPPB-I100003
Abstract
Description
Antibody or antigen-binding fragment thereof, antibody-drug conjugate and use thereof Technical Field
[0001] The present invention belongs to the field of antibodies, and specifically relates to an antibody that specifically binds to mammalian, especially human, SEZ6, and a preparation method, a conjugate thereof, and an application thereof. The drug is prepared by connecting an anti-SEZ6 antibody to an anti-tumor drug 9106 via a linker. Background Art
[0002] Antibody-drug conjugates (ADCs) are designed to selectively deliver cytotoxins into tumor cells by coupling them to antibodies that selectively bind to the surface of cancer cells. These cytotoxins are then internalized through antigen-antibody mediated internalization. When the toxins accumulate to a certain level, they kill the tumor cells. ADCs consist of three parts: an antibody, a linker, and a toxin. ADCs can effectively improve the precise targeting of toxins to tumors and increase the therapeutic window, so target selection for ADCs is crucial. These toxins need to be specifically and highly expressed in tumors and not expressed in normal tissues.
[0003] Small cell lung cancer (SCLC) is a highly malignant tumor, diagnosed annually in approximately 250,000 people worldwide, accounting for approximately 15% of lung cancer cases. 70% of these patients have metastatic disease at the time of diagnosis. Tumor development is closely linked to smoking and is associated with mutations in multiple tumor suppressor genes. The median survival for diagnosed patients is only 8–12 months, with very few surviving for more than 5 years. The standard first-line treatment for SCLC is a platinum-based chemotherapy plus etoposide. Patients have a high response rate to first-line chemotherapy, but new effective treatment options are lacking for patients who develop relapse and drug resistance. Second-line treatment with topotecan has a low response rate and does not significantly improve survival. New breakthroughs and advances in the treatment of SCLC are urgently needed (Nature Reviews Clinical Oncology, volume 14, pages 549–561 (2017)).
[0004] Human SEZ6 (epilepsy-associated protein 6, hereinafter referred to as hSEZ6) is a single-pass transmembrane protein primarily expressed in the brain and virtually absent in the periphery. In neurological diseases, knockout of SEZ6 in mice promotes the formation of short, multi-synapses (Neuron 56, 621–639, November 21, 2007). SEZ6 is a substrate of BACE1, and soluble SEZ6 in cerebrospinal fluid can serve as a marker for Alzheimer's disease (Molecular Neurodegeneration 2016, 11:67).
[0005] SEZ6, a tumor-specific marker, is highly expressed in neuroendocrine tumors. Immunohistochemical analysis of clinical specimens has shown that SEZ6 is highly expressed in small cell lung cancer, with expression levels significantly higher than in normal tissue. In tumor tissue sections from 174 small cell lung cancer patients, approximately 70% of the patients' tumors were positive for SEZ6 (Patent Publication: US2016287720A1).
[0006] Based on the high expression of SEZ6 in tumors, AbbVie Pharmaceuticals developed an ADC targeting SEZ6, ABBV-011, for the treatment of small cell lung cancer (patent publication: WO2013126810A). This ADC utilizes calicheamicin as a toxin, has a DAR value of 2, and employs a non-degradable linker. This ADC entered Phase I clinical trials in 2019 (NCT03639194).
[0007] This patent utilizes the high-affinity and high-endocytosis SEZ6 antibody, obtained through mouse and camel immunization, and conjugated to the toxin compound 169106 (published patent: WO2020063676A) to create an innovative ADC drug. 169106 is a topoisomerase I inhibitor (also described herein as 9106). Previous studies have demonstrated that this antibody-toxin conjugate exhibits good drugability, in vivo anti-tumor activity, and safety.
[0008] Summary of the Invention
[0009] The present disclosure relates to anti-SEZ6 antibodies or antigen-binding fragments thereof, ADCs thereof, and their medical uses. More specifically, the present disclosure provides monoclonal antibodies or antigen-binding fragments that bind to the amino acid sequence or three-dimensional structure of the ECD region of SEZ6, and ADC drugs conjugated with a cytotoxic substance, exitecan analog.
[0010] In some embodiments, the present disclosure provides an anti-SEZ6 antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region (VH) or a heavy chain single domain (VHH), wherein the heavy chain variable region or heavy chain single domain comprises: (1) the heavy chain HCDR1, HCDR2, HCDR3 as shown in the amino acid sequences of SEQ ID NOs: 37, 38 and 39; or (2) the heavy chain HCDR1, HCDR2, HCDR3 as shown in the amino acid sequences of SEQ ID NOs: 43, 44 and 45; or (3) the heavy chain HCDR1, HCDR2, HCDR3 as shown in the amino acid sequences of SEQ ID NOs: 49, 50 and 51; or (4) the heavy chain HCDR1, HCDR2, HCDR3 as shown in the amino acid sequences of SEQ ID NOs: 65, 66 and 67; or (5) the heavy chain HCDR1, HCDR2, HCDR3 as shown in the amino acid sequences of SEQ ID NOs: 68, 69 and 70.
[0011] In some embodiments, the present disclosure provides an anti-DLL3 antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the heavy chain variable region and the light chain variable region comprise: (1) heavy chain HCDR1, HCDR2, HCDR3 as set forth in the amino acid sequences of SEQ ID NOs: 37, 38 and 39, and light chain LCDR1, LCDR2 and LCDR3 as set forth in the amino acid sequences of SEQ ID NOs: 40, 41 and 42; or (2) heavy chain HCDR1, HCDR2, HCDR3 as set forth in the amino acid sequences of SEQ ID NOs: 43, 44 and 45, and light chain LCDR1, LCDR2 and LCDR3 as set forth in the amino acid sequences of SEQ ID NOs: 46, 47 and 48; or (3) heavy chain HCDR1, HCDR2, HCDR3 as set forth in the amino acid sequences of SEQ ID NOs: 49, 50 and 51, and light chain LCDR1, LCDR2 and LCDR3 as set forth in the amino acid sequences of SEQ ID NOs: 52, 53 and 54.
[0012] In some embodiments, the present disclosure provides an anti-DLL3 antibody or an antigen-binding fragment thereof, wherein the heavy chain single domain comprises an amino acid sequence as set forth in SEQ ID NO: 63, or a sequence at least 85%, 90%, 95%, or 99% homologous thereto; or as set forth in SEQ ID NO: 64, or a sequence at least 85%, 90%, 95%, or 99% homologous thereto.
[0013] In some embodiments, the present disclosure provides an anti-DLL3 antibody or an antigen-binding fragment thereof, wherein the heavy chain single domain comprises the amino acid sequence shown in SEQ ID NO: 63 or SEQ ID NO: 64.
[0014] In some embodiments, the present disclosure provides an anti-DLL3 antibody or an antigen-binding fragment thereof, wherein the heavy chain single domain amino acid sequence is as shown in SEQ ID NO: 63, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto; or as shown in SEQ ID NO: 64, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto.
[0015] In some embodiments, the present disclosure provides an anti-DLL3 antibody or an antigen-binding fragment thereof, wherein the heavy chain single domain amino acid sequence is shown in SEQ ID NO: 63 or SEQ ID NO: 64.
[0016] In some embodiments, the present disclosure provides an anti-DLL3 antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein: the heavy chain variable region comprises an amino acid sequence as shown in SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 35, or a sequence at least 85%, 90%, 95%, or 99% homologous thereto; and the light chain variable region comprises an amino acid sequence as shown in SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, or a sequence at least 85%, 90%, 95%, or 99% homologous thereto.
[0017] In some embodiments, the present disclosure provides an anti-DLL3 antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein: the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 35; and the light chain variable region comprises the amino acid sequence shown in SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36.
[0018] In some embodiments, the present disclosure provides an anti-DLL3 antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein: the heavy chain variable region amino acid sequence is selected from SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 35, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto; and the light chain variable region amino acid sequence is selected from SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto.
[0019] In some embodiments, the present disclosure provides an anti-SEZ6 antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein: the heavy chain variable region amino acid sequence is selected from SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 35; the light chain variable region amino acid sequence is selected from SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36.
[0020] In some embodiments, the present disclosure provides an anti-SEZ6 antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein: (1) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 29, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 30, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto; or (2) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 31, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 32, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto; or (3) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 31, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: NO: 34, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto; or (4) the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO: 35, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto, and the light chain variable region comprises the amino acid sequence shown in SEQ ID NO: 36, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto.
[0021] In some embodiments, the present disclosure provides an anti-SEZ6 antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein: (1) the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO: 29, and the light chain variable region comprises the amino acid sequence shown in SEQ ID NO: 30; or (2) the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO: 31, and the light chain variable region comprises the amino acid sequence shown in SEQ ID NO: 32; or (3) the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO: 31, and the light chain variable region comprises the amino acid sequence shown in SEQ ID NO: 34; or (4) the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO: 35, and the light chain variable region comprises the amino acid sequence shown in SEQ ID NO: 36.
[0022] In some embodiments, the present disclosure provides an anti-SEZ6 antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region and the light chain variable region comprise: (1) the heavy chain variable region amino acid sequence as shown in SEQ ID NO: 29, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto, and the light chain variable region amino acid sequence as shown in SEQ ID NO: 30, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto; or (2) the heavy chain variable region amino acid sequence as shown in SEQ ID NO: 31, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto, and the light chain variable region amino acid sequence as shown in SEQ ID NO: 32, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto; or (3) the heavy chain variable region amino acid sequence as shown in SEQ ID NO: 31, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto, and the light chain variable region amino acid sequence as shown in SEQ ID NO: NO: 34, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto; or (4) the heavy chain variable region amino acid sequence is as shown in SEQ ID NO: 35, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto, and the light chain variable region amino acid sequence is as shown in SEQ ID NO: 36, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto.
[0023] In some embodiments, the present disclosure provides an anti-SEZ6 antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region and the light chain variable region comprise: (1) the heavy chain variable region amino acid sequence as shown in SEQ ID NO: 29, and the light chain variable region amino acid sequence as shown in SEQ ID NO: 30; or (2) the heavy chain variable region amino acid sequence as shown in SEQ ID NO: 31, and the light chain variable region amino acid sequence as shown in SEQ ID NO: 32; or (3) the heavy chain variable region amino acid sequence as shown in SEQ ID NO: 31, and the light chain variable region amino acid sequence as shown in SEQ ID NO: 34; or (4) the heavy chain variable region amino acid sequence as shown in SEQ ID NO: 35, and the light chain variable region amino acid sequence as shown in SEQ ID NO: 36.
[0024] In some embodiments, the aforementioned anti-DLL3 antibody or antigen-binding fragment thereof is selected from the group consisting of Fab, Fab', F(ab')2, single-chain antibody (scFv), single-domain antibody (sdAb), dimerized V region (diabody), disulfide bond-stabilized V region (dsFv) and an antigen-binding fragment of a peptide comprising CDRs.
[0025] In some embodiments, the aforementioned anti-SEZ6 antibody or antigen-binding fragment thereof comprises an antibody constant region; wherein the heavy chain constant region is derived from human IgG1, IgG2, IgG3 or IgG4, or has at least 95% sequence identity thereto, or a variant thereof; and / or the light chain constant region is derived from a human antibody κ or λ chain, or has at least 95% sequence identity thereto, or a variant thereof; preferably, the amino acid sequence of the heavy chain constant region is derived from human IgG1, or has at least 95% sequence identity thereto, or a variant thereof; and / or the light chain constant region is derived from a human antibody κ chain, or has at least 95% sequence identity thereto, or a variant thereof; more preferably, the amino acid sequence of the heavy chain constant region is as shown in SEQ ID NO: 33, and / or the amino acid sequence of the light chain constant region is as shown in SEQ ID NO: 59.
[0026] In some embodiments, the aforementioned anti-DLL3 antibody or antigen-binding fragment thereof comprises a heavy chain and a light chain, wherein: (1) the heavy chain comprises the amino acid sequence of SEQ ID NO:55, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto, and the light chain comprises the amino acid sequence of SEQ ID NO:56, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto; or (2) the heavy chain comprises the amino acid sequence of SEQ ID NO:57, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto, and the light chain comprises the amino acid sequence of SEQ ID NO:58, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto; or (3) the heavy chain comprises the amino acid sequence of SEQ ID NO:57, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto, and the light chain comprises the amino acid sequence of SEQ ID NO: NO:60, or a sequence having at least 85%, 90%, 95%, 99% homology thereto; or (4) the heavy chain comprises the amino acid sequence as shown in SEQ ID NO:61, or a sequence having at least 85%, 90%, 95%, 99% homology thereto, and the light chain comprises the amino acid sequence as shown in SEQ ID NO:62, or a sequence having at least 85%, 90%, 95%, 99% homology thereto.
[0027] In some embodiments, the aforementioned anti-DLL3 antibody or antigen-binding fragment thereof comprises a heavy chain and a light chain, wherein: (1) the heavy chain comprises the amino acid sequence shown in SEQ ID NO: 55, and the light chain comprises the amino acid sequence shown in SEQ ID NO: 56; or (2) the heavy chain comprises the amino acid sequence shown in SEQ ID NO: 57, and the light chain comprises the amino acid sequence shown in SEQ ID NO: 58; or (3) the heavy chain comprises the amino acid sequence shown in SEQ ID NO: 57, and the light chain comprises the amino acid sequence shown in SEQ ID NO: 60; or (4) the heavy chain comprises the amino acid sequence shown in SEQ ID NO: 61, and the light chain comprises the amino acid sequence shown in SEQ ID NO: 62.
[0028] In some embodiments, the aforementioned anti-DLL3 antibody or antigen-binding fragment thereof comprises a heavy chain and a light chain, wherein the heavy chain and the light chain comprise: (1) a heavy chain sequence as set forth in SEQ ID NO:55 or a sequence having at least 85%, 90%, 95%, 99% homology thereto, and a light chain sequence as set forth in SEQ ID NO:56 or a sequence having at least 85%, 90%, 95%, 99% homology thereto; or (2) a heavy chain sequence as set forth in SEQ ID NO:57 or a sequence having at least 85%, 90%, 95%, 99% homology thereto, and a light chain sequence as set forth in SEQ ID NO:58 or a sequence having at least 85%, 90%, 95%, 99% homology thereto; or (3) a heavy chain sequence as set forth in SEQ ID NO:57 or a sequence having at least 85%, 90%, 95%, 99% homology thereto, and a light chain sequence as set forth in SEQ ID NO:60 or a sequence having at least 85%, 90%, 95%, 99% homology thereto; or (4) a heavy chain sequence as set forth in SEQ ID NO: The heavy chain sequence shown in NO:61 or a sequence having at least 85%, 90%, 95%, 99% homology thereto, and the light chain sequence shown in SEQ ID NO:62, or a sequence having at least 85%, 90%, 95%, 99% homology thereto.
[0029] In some embodiments, the aforementioned anti-SEZ6 antibody or antigen-binding fragment thereof comprises a heavy chain and a light chain, wherein the heavy chain and the light chain comprise: (1) the heavy chain sequence shown in SEQ ID NO: 55 and the light chain sequence shown in SEQ ID NO: 56; or (2) the heavy chain sequence shown in SEQ ID NO: 57 and the light chain sequence shown in SEQ ID NO: 58; or (3) the heavy chain sequence shown in SEQ ID NO: 57 and the light chain sequence shown in SEQ ID NO: 60; or (4) the heavy chain sequence shown in SEQ ID NO: 61 and the light chain sequence shown in SEQ ID NO: 62.
[0030] In some embodiments, the aforementioned anti-DLL3 antibody or antigen-binding fragment thereof consists of a heavy chain, wherein: (1) the heavy chain comprises the amino acid sequence as shown in SEQ ID NO:71, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto; or (2) the heavy chain comprises the amino acid sequence as shown in SEQ ID NO:72, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto.
[0031] In some embodiments, the aforementioned anti-SEZ6 antibody or antigen-binding fragment thereof consists of a heavy chain, wherein: (1) the heavy chain comprises the amino acid sequence shown in SEQ ID NO: 71; or (2) the heavy chain comprises the amino acid sequence shown in SEQ ID NO: 72.
[0032] In some embodiments, the aforementioned anti-DLL3 antibody or antigen-binding fragment thereof, which consists of a heavy chain, comprises: (1) the heavy chain sequence shown in SEQ ID NO: 71 or a sequence having at least 85%, 90%, 95%, or 99% homology thereto; or (2) the heavy chain sequence shown in SEQ ID NO: 72 or a sequence having at least 85%, 90%, 95%, or 99% homology thereto.
[0033] In some embodiments, the aforementioned anti-DLL3 antibody or antigen-binding fragment thereof, which consists of a heavy chain, comprises: (1) the heavy chain sequence shown by SEQ ID NO: 71; or (2) the heavy chain sequence shown by SEQ ID NO: 72.
[0034] In another aspect, the present disclosure provides an isolated anti-DLL3 antibody or antigen-binding fragment thereof that competes for binding to DLL3 with any of the aforementioned antibodies or antigen-binding fragments thereof.
[0035] In another aspect, the present invention discloses an isolated nucleic acid encoding any of the aforementioned anti-DLL3 antibodies or antigen-binding fragments thereof.
[0036] In another aspect, the present invention discloses a vector comprising the nucleic acid as described above.
[0037] In yet another aspect, the present disclosure provides a host cell comprising the vector as described above.
[0038] In one aspect, the present disclosure provides a method for preparing an anti-DLL3 antibody or an antigen-binding fragment thereof, comprising culturing the aforementioned host cell under conditions suitable for expressing the anti-DLL3 antibody or the antigen-binding fragment thereof.
[0039] In yet another aspect, the present disclosure provides an antibody-drug conjugate or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, comprising the anti-DLL3 antibody or antigen-binding fragment thereof as described in any of the preceding items.
[0040] In some embodiments, the aforementioned antibody-drug conjugate or its pharmaceutically acceptable salt or solvate, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, wherein the drug is selected from cytotoxic agents, radiolabels, fluorophores, chromophores, imaging agents, immunomodulators, angiogenesis inhibitors, cell proliferation inhibitors, pro-apoptotic agents, cell lytic enzymes, and any combination thereof; preferably, the drug is selected from: DNA damaging agents, topoisomerase inhibitors, microtubule inhibitors, protein degraders, STING agonists, and any combination thereof.
[0041] In some embodiments, the aforementioned antibody-drug conjugate or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, has a structure represented by general formula (I):
[0042] Wherein, Dr is selected from the group consisting of camptothecin, auristatin, maytansinoid, pyrrolobenzodiazepine (PBD), calicheamicin, duocarmycin, daunorubicin, doxorubicin, calicheamicin, anthramycin, neomycin, amatoxin, hemicycline, eribulin, tubulysin, and analogs or derivatives thereof. Preferably, Dr is selected from the group consisting of exatecan, MMAE, MMAF, MMAD, SN-38, DM1, DM4, and pyrrolobenzodiazepine (PBD) dimer;
[0043] n is 1 to 10, preferably n is 2 to 8, more preferably n is 3 to 5 or 4 to 8, n is a decimal or an integer, further preferably n is 4 to 6, n is a decimal or an integer, further preferably n is 5 to 6, n is a decimal or an integer, further preferably, n is 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5 or 8;
[0044] L and Y are linker units; Pc is the aforementioned anti-SEZ6 antibody or an antigen-binding fragment thereof.
[0045] In some embodiments, the aforementioned antibody-drug conjugate or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, has a structure represented by the general formula (Pc-LY-Dr), general formula (II), general formula (III), or general formula (IV):
[0046] Wherein: Y is selected from -O-(CR a R b ) m -CR 1R 2 -C(O)-, -O-CR 1 R 2 -(CR a R b ) m -、-O-CR 1 R 2 -、-NH-(CR a R b ) m -CR 1 R 2 -C(O)- or -S-(CR a R b ) m -CR 1 R 2 -C(O)-;R a and R b are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen, an alkyl group, a haloalkyl group, a deuterated alkyl group, an alkoxy group, a hydroxyl group, an amino group, a cyano group, a nitro group, a hydroxyalkyl group, a cycloalkyl group or a heterocyclic group; or, R a and R b Together with the carbon atom to which it is attached, it forms a cycloalkyl group or a heterocyclic group; R 1 R is selected from halogen, haloalkyl, deuterated alkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, heterocyclyl, aryl or heteroaryl; 2 is selected from hydrogen, halogen, haloalkyl, deuterated alkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, heterocyclic, aryl or heteroaryl; or, R 1 and R 2 Together with the carbon atom to which it is attached, it forms a cycloalkyl or heterocyclic group; or, R a and R 2 The carbon atom to which it is attached forms a cycloalkyl or heterocyclic group; m is an integer from 0 to 4; n is from 1 to 10, preferably n is from 2 to 8, more preferably n is from 3 to 5 or 4 to 8, n is a decimal or an integer, further preferably n is from 4 to 6, n is a decimal or an integer, further preferably n is from 5 to 6, n is a decimal or an integer, further preferably, n is 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5 or 8; L is a linker unit; Pc is an anti-SEZ6 antibody or antigen-binding fragment thereof as described in any of the preceding items.
[0047] In some embodiments, the aforementioned antibody-drug conjugate or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, meso racemate, racemate, enantiomer, diastereomer, or a mixture thereof, wherein n is 2 to 8, preferably 3 to 5 or 4 to 8, n is a decimal or an integer, more preferably 4 to 6, n is a decimal or an integer, further preferably 5 to 6, n is a decimal or an integer, and further preferably, n is 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5 or 8.
[0048] In some embodiments, the antibody-drug conjugate or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, meso-racemate, racemate, enantiomer, diastereomer, or mixture thereof as described in any of the preceding items, wherein: Y is -O-(CR a R b ) m -CR 1 R 2 -C(O)-;R a and R b are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen or an alkyl group; R 1 is a halogenated alkyl or C 3-6 Cycloalkyl; R 2 Selected from hydrogen atom, halogenated alkyl or C 3-6 Cycloalkyl; or, R 1 and R 2 Together with the carbon atom to which it is attached, it forms C 3-6 Cycloalkyl; m is 0 or 1.
[0049] In some embodiments, the antibody-drug conjugate or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof as described in any of the preceding items, wherein Y is selected from:
[0050] In some embodiments, the antibody-drug conjugate or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof as described in any of the preceding items, wherein the O end of Y is connected to the linker unit L.
[0051] In some embodiments, the antibody-drug conjugate or its pharmaceutically acceptable salt or solvate as described in any of the preceding items, or its tautomer, meso-racemate, racemate, enantiomer, diastereomer, or mixture thereof, wherein the linker unit -L- is -L 1 -L 2 -L 3 -L4 -,
[0052] L 1 for s 1 is an integer from 2 to 8; L 2 is a chemical bond; L 3 is a tetrapeptide residue; L 4 -NR 5 (CR 6 R 7 )t-,R 5 、R 6 or R 7 are the same or different and are each independently a hydrogen atom or an alkyl group, and t is 1 or 2.
[0053] In some embodiments, the antibody-drug conjugate or its pharmaceutically acceptable salt or solvate as described in any of the preceding items, or its tautomer, meso-racemate, racemate, enantiomer, diastereomer, or mixture thereof, wherein the linker unit -L- is -L 1 -L 2 -L 3 -L 4 -,
[0054] L 1 for s 1 and s 2 Independently selected from integers from 0 to 8; preferably s 1 is 2, s 2 is an integer from 2 to 8; more preferably, s 1 is 2, s 2 2, 3, 4, 5 or 6; L 2 is a chemical bond; L 3 is a tetrapeptide residue; L 4 -NR 5 (CR 6 R 7 )t-,R 5 、R 6 or R 7 are the same or different and are each independently a hydrogen atom or an alkyl group, and t is 1 or 2.
[0055] In some embodiments, the antibody-drug conjugate or its pharmaceutically acceptable salt or solvate as described in any of the preceding items, or its tautomer, meso-racemate, racemate, enantiomer, diastereomer, or mixture thereof, wherein the linker unit -L-, wherein L 1 The end is connected to PC, L 4 Connect the Y end.
[0056] In some embodiments, the antibody-drug conjugate or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof as described in any of the preceding items, wherein the L 3 The tetrapeptide residue is an amino acid residue formed by two or more amino acids selected from phenylalanine, glycine, valine, lysine, citrulline, serine, glutamic acid, and aspartic acid; preferably, the tetrapeptide residue is GGFG.
[0057] In some embodiments, the antibody-drug conjugate or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof as described in any of the preceding items, wherein the -LY- is the following structure:
[0058] L 2 is a chemical bond; L 3 is the tetrapeptide residue of GGFG; R 1 is a halogenated alkyl or C 3-6 Cycloalkyl; R 2 Selected from hydrogen atom, halogenated alkyl or C 3-6 Cycloalkyl; or, R 1 and R 2 Together with the carbon atom to which it is attached, it forms C 3-6 Cycloalkyl; R 5 、R 6 or R 7 are the same or different and are each independently a hydrogen atom or an alkyl group; 1 is an integer from 2 to 8; m is an integer from 0 to 4.
[0059] In some embodiments, the antibody-drug conjugate or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof as described in any of the preceding items, wherein -LY- is selected from:
[0060] In some embodiments, the antibody-drug conjugate or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof as described in any of the preceding items is of the general formula (Pc-L a -Y-Dr) or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, meso-racemate, racemate, enantiomer, diastereomer, or mixture thereof:
[0061] Where: W is selected from C 1-8 Alkyl, C 1-8 Alkyl-cycloalkyl or straight chain heteroalkyl of 1 to 8 atoms, said heteroalkyl containing 1 to 3 heteroatoms selected from N, O or S, wherein said C 1-8 Alkyl, cycloalkyl and straight-chain heteroalkyl are each independently optionally further substituted with one or more substituents selected from halogen, hydroxy, cyano, amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl; L 2 Selected from-NR 4 (CH2CH2O) p1 CH2CH2C(O)-、-NR 4 (CH2CH2O) p1 CH2C(O)-、-S(CH2) p1 C(O)- or chemical bond, p 1 is an integer from 1 to 20; L 3 is a peptide residue consisting of 2 to 7 amino acids, which may be substituted or unsubstituted. When substituted, the substituent may be substituted at any available attachment point, wherein the substituent is one or more independently selected from halogen, hydroxy, cyano, amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl; R 1 R is selected from halogen, haloalkyl, deuterated alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; 2 is selected from hydrogen, halogen, haloalkyl, deuterated alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl; or, R 1 and R 2 Together with the carbon atom to which it is attached, it forms a cycloalkyl group or a heterocyclic group; R 4 and R 5 are the same or different and are each independently selected from a hydrogen atom, an alkyl group, a halogenated alkyl group, a deuterated alkyl group and a hydroxyalkyl group; R 6 and R 7 are the same or different and are each independently selected from a hydrogen atom, a halogen, an alkyl group, a haloalkyl group, a deuterated alkyl group and a hydroxyalkyl group; m is an integer from 0 to 4; n is from 1 to 10, preferably n is from 2 to 8, more preferably n is from 3 to 5 or from 4 to 8, n is a decimal or an integer, further preferably n is from 4 to 6, n is a decimal or an integer, further preferably n is from 5 to 6, n is a decimal or an integer, further preferably, n is 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5 or 8; Pc is an anti-SEZ6 antibody or an antigen-binding fragment thereof as described in any of the preceding items.
[0062] In some embodiments, the antibody-drug conjugate represented by the general formula (Pc-LY-Dr) as described above, or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, meso-racemate, racemate, enantiomer, diastereomer, or mixture thereof, is a compound of the general formula (Pc-L-Y-Dr). b -Y-Dr) or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, meso-racemate, racemate, enantiomer, diastereomer, or mixture thereof:
[0063] Where: s 1 is an integer from 2 to 8; R 1 、R 2 、R 5 ~R 7 , m and n are as defined in the general formula (Pc-La-Y-Dr).
[0064] In some embodiments, the antibody-drug conjugate as described above or its pharmaceutically acceptable salt or solvate, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, is selected from:
[0065] n is 1 to 10, preferably n is 2 to 8, more preferably n is 3 to 5 or 4 to 8, n is a decimal or an integer, further preferably n is 4 to 6, n is a decimal or an integer, further preferably n is 5 to 6, n is a decimal or an integer, further preferably, n is 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5 or 8;
[0066] Pc is the aforementioned anti-SEZ6 antibody or an antigen-binding fragment thereof.
[0067] In some embodiments, the antibody-drug conjugate as described above or its pharmaceutically acceptable salt or solvate, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, is selected from:
[0068] wherein n is 1 to 10, preferably n is 2 to 8, more preferably n is 3 to 5 or 4 to 8, n is a decimal or an integer, further preferably n is 4 to 6, n is a decimal or an integer, further preferably n is 5 to 6, n is a decimal or an integer, further preferably, n is 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5 or 8.
[0069] The present disclosure further provides a method for preparing a method of preparing a method of the general formula (Pc-L a -Y-Dr) or a pharmaceutically acceptable salt or solvate thereof, comprising the following steps:
[0070] After Pc reduction, with the general formula (L a -Y-Dr) coupling reaction to obtain the general formula (Pc-L a -Y-Dr) shown in the compound; wherein: Pc is the anti-SEZ6 antibody or antigen-binding fragment thereof as described in any of the above items. W, L 2 、L 3 、R 1 、R 2 、R 5 ~R 7 , m and n are as in the general formula (Pc-L a -Y-Dr) as defined.
[0071] In another embodiment, another method is provided, wherein the general formula L a -Y-Dr is the general formula L b -Y-Dr represented by the compound:
[0072] or its tautomers, meso-racemates, racemates, enantiomers, diastereomers, or mixtures thereof, or pharmaceutically acceptable salts thereof, wherein R 1 、R 2 、R 5 ~R 7 、s 1 and m as the general formula Pc-L b -Y-As defined in Dr.
[0073] In a preferred embodiment of the present disclosure, according to the general formula (Pc-L a -Y-Dr) or general formula (Pc-L b -Y-Dr) or a pharmaceutically acceptable salt or solvate thereof, wherein the general formula (L a -Y-Dr) or the compound represented by the general formula (L b -Y-Dr) is selected from the group consisting of:
[0074] In another aspect, the present disclosure provides a kit comprising the anti-DLL3 antibody or antigen-binding fragment thereof described herein, or the antibody-drug conjugate or pharmaceutically acceptable salt or solvate thereof described herein, or a tautomer, mesoform, racemate, enantiomer, diastereomer, or mixture thereof.
[0075] In another aspect, the present disclosure provides a pharmaceutical composition comprising the anti-DLL3 antibody or antigen-binding fragment thereof according to the present disclosure, or the antibody-drug conjugate according to the present disclosure or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, meso-racemate, racemate, enantiomer, diastereomer, or mixture thereof, and one or more pharmaceutically acceptable carriers.
[0076] In another aspect, the present disclosure provides use of an anti-DLL3 antibody or antigen-binding fragment thereof, an antibody-drug conjugate, or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesoform, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutical composition comprising the same, for the preparation of a medicament for treating a disease or condition mediated by DLL3, wherein the disease or condition mediated by DLL3 is a cancer with high DLL3 expression.
[0077] On the other hand, the present disclosure provides use of the antibody-drug conjugate according to the present disclosure or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutical composition comprising the same, in the preparation of a medicament for treating or preventing a tumor or cancer; wherein the cancer is preferably: lung cancer, breast cancer, liver cancer, hepatobiliary cancer, pancreatic cancer, gastric cancer, gastrointestinal cancer, intestinal cancer, colon cancer, colorectal cancer, kidney cancer, clear cell renal cell carcinoma, ovarian cancer, endometrial cancer, cervical cancer, bladder cancer, prostate cancer, testicular cancer, skin cancer, melanoma, leukemia, lymphoma, or bone cancer.
[0078] The active compound may be formulated for administration by any appropriate route, preferably in a unit dosage form, or in a form that a patient can self-administer as a single dose. A unit dosage form of a compound or composition of the present disclosure may be in the form of a tablet, capsule, cachet, bottled solution, powder, granules, lozenge, suppository, reconstituted powder, or liquid formulation.
[0079] The dosage of the compound or composition used in the disclosed methods of treatment will generally vary with the severity of the disease, the weight of the patient and the relative efficacy of the compound. However, as a general guide, a suitable unit dosage may be 0.1 to 1000 mg.
[0080] The pharmaceutical composition of the present disclosure may contain one or more excipients in addition to the active compound, selected from the following ingredients: fillers (diluents), binders, wetting agents, disintegrants or excipients, etc. Depending on the administration method, the composition may contain 0.1 to 99% by weight of the active compound.
[0081] The anti-SEZ6 antibodies or antigen-binding fragments disclosed herein have no nonspecific binding, exhibit superior antigen binding, and possess unique binding epitopes. The antibody-drug conjugates disclosed herein, or pharmaceutically acceptable salts or solvates thereof, or their tautomers, mesoforms, racemates, enantiomers, diastereomers, or mixtures thereof, exhibit excellent in vitro cytotoxic and in vivo tumor inhibition effects, as well as excellent in vivo pharmacokinetic parameters.
[0082] Detailed Description of the Invention
[0083] 1. Terminology
[0084] Unless otherwise defined, all technical and scientific terms used herein are consistent with the common understanding of one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can be used to practice or test the present disclosure, preferred methods and materials are described herein. When describing and claiming the present disclosure, the following terms are used in accordance with the following definitions.
[0085] When a trade name is used in this disclosure, applicant intends to include the formulations of the trade name product, the generic version of the trade name product, and the active drug portion of the trade name product.
[0086] Unless otherwise stated, the terms used in the specification and claims have the following meanings.
[0087] The term "drug" refers to cytotoxic drugs, which are represented by Dr. They are chemical molecules that have a strong ability to disrupt the normal growth of tumor cells. In principle, cytotoxic drugs can kill tumor cells at sufficiently high concentrations. However, due to their lack of specificity, they can also cause apoptosis of normal cells while killing tumor cells, leading to serious side effects. The term includes toxins, such as small molecule toxins or enzyme-active toxins of bacterial, fungal, plant or animal origin, radioactive isotopes (such as At 211 , I 131 , I 125 、Y 90 、Re 186 、Re 188 、Sm 153 、Bi 212 、P 32 and radioactive isotopes of Lu), toxic drugs, chemotherapeutic drugs, antibiotics and nucleolytic enzymes, preferably toxic drugs.
[0088] The term "linker unit (or linker fragment)" refers to a chemical structure fragment or bond that is connected to the antibody at one end and to the drug at the other end, and can also be connected to other linkers before being connected to the drug. 1 To L 4 , where L 1 The end is connected to the antibody, L 4 The end is connected to the structural unit Y and then to the drug (Dr).
[0089] Linkers, including extenders, spacers, and amino acid units, can be synthesized by methods known in the art, such as those described in US 2005-0238649 A1. The linker can be a "cleavable linker" that facilitates release of the drug in the cell. For example, an acid-labile linker (e.g., a hydrazone), a protease-sensitive (e.g., a peptidase-sensitive) linker, a photolabile linker, a dimethyl linker, or a disulfide-containing linker can be used (Chari et al., Cancer Research 52: 127-131 (1992); U.S. Patent No. 5,208,020).
[0090] The term "ligand-drug conjugate" refers to a ligand linked to a biologically active drug via a stable linker. In the present disclosure, a "ligand-drug conjugate" is preferably an antibody-drug conjugate (ADC), which refers to a monoclonal antibody or antibody fragment linked to a biologically active toxic drug via a stable linker.
[0091] The three letter and one letter codes for amino acids used in this disclosure are as described in J. biol. chem, 243, p3558 (1968).
[0092] The term "antibody" refers to immunoglobulins, which are tetrapeptide chains composed of two identical heavy chains and two identical light chains connected by interchain disulfide bonds. The amino acid composition and order of the constant region of immunoglobulins' heavy chains vary, resulting in different antigenicity. Consequently, immunoglobulins can be divided into five classes, or isotypes, namely IgM, IgD, IgG, IgA, and IgE, with their corresponding heavy chains being μ, δ, γ, α, and ε, respectively. Within the same class, Igs are further divided into subclasses based on the amino acid composition of their hinge regions and the number and location of heavy chain disulfide bonds. For example, IgG can be divided into IgG1, IgG2, IgG3, and IgG4. Light chains are classified as either kappa or lambda chains based on differences in their constant regions. Each of the five Ig classes can have either kappa or lambda chains.
[0093] The approximately 110 amino acids near the N-terminus of an antibody's heavy and light chains vary greatly in sequence and constitute the variable region (Fv region). The remaining amino acid sequences near the C-terminus are relatively stable and constitute the constant region. The variable region comprises three hypervariable regions (HVRs) and four framework regions (FRs), whose sequences are relatively conserved. These three hypervariable regions determine the antibody's specificity and are also known as complementarity-determining regions (CDRs). Each light chain variable region (LCVR) and heavy chain variable region (HCVR) consists of three CDR regions and four FR regions, arranged in the following order from amino to carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The three CDR regions of the light chain are LCDR1, LCDR2, and LCDR3; the three CDR regions of the heavy chain are HCDR1, HCDR2, and HCDR3. The number and position of the CDR amino acid residues in the LCVR and HCVR regions of the antibodies or antigen-binding fragments described in the present disclosure conform to the well-known Kabat numbering convention (LCDR1-3, HCDR2-3), or conform to the numbering convention of Kabat and Chothia (HCDR1).
[0094] The term "fully human antibody" or "fully human antibody", also known as "fully human monoclonal antibody", is an antibody whose variable and constant regions are both human, eliminating immunogenicity and toxic side effects. The development of monoclonal antibodies has gone through four stages, namely: murine monoclonal antibodies, chimeric monoclonal antibodies, humanized monoclonal antibodies and fully human monoclonal antibodies. The relevant technologies for the preparation of fully human antibodies mainly include: human hybridoma technology, EBV-transformed B lymphocyte technology, phage display technology (phage display), transgenic mouse antibody preparation technology (transgenic mouse) and single B cell antibody preparation technology, etc. The "fully human antibody" in this disclosure is obtained using phage display technology. Phage display technology separates B cells from human PBMC, spleen, and lymph node tissues, constructs a natural single-chain phage human antibody library, or screens the obtained antibodies by immunizing transgenic mice that can express human antibody light and heavy chains.
[0095] The term "antigen-binding fragment" refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen. It has been shown that fragments of a full-length antibody can be used to perform the antigen-binding function of an antibody. Examples of binding fragments included in "antigen-binding fragments" include: (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL, and CH1 domains; (ii) a F(ab')2 fragment, a bivalent fragment comprising two Fab fragments connected by a disulfide bridge on the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) a Fv fragment consisting of the VH and VL domains of a single arm of an antibody; (v) a single domain or dAb fragment (Ward et al., (1989) Nature 341: 544-546), which consists of a VHH domain; and (vi) an isolated complementarity determining region (CDR) or (vii) a combination of two or more isolated CDRs, optionally connected by a synthetic linker. In addition, although the two domains VL and VH of the Fv fragment are encoded by separate genes, they can be connected by synthetic linkers using recombinant methods, so that they can be produced as a single protein chain in which the VL and VH regions are paired to form a monovalent molecule (called single-chain Fv (scFv); see, for example, Bird et al. (1988) Science 242: 423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci USA 85: 5879-5883). Such single-chain antibodies are also intended to be included in the term "antigen-binding fragment" of an antibody. Such antibody fragments are obtained using conventional techniques known to those skilled in the art, and the fragments are screened for functionality in the same manner as for intact antibodies. Antigen-binding portions can be produced by recombinant DNA technology or by enzymatic or chemical fragmentation of intact immunoglobulins. The antibodies can be of different isotypes, for example, IgG (eg, IgG1, IgG2, IgG3, or IgG4 subtype), IgAl, IgA2, IgD, IgE, or IgM antibodies.
[0096] Fab is an antibody fragment having a molecular weight of approximately 50,000 and antigen-binding activity, among fragments obtained by treating IgG antibody molecules with the protease papain (cleaving the amino acid residue at position 224 of the H chain), in which approximately half of the N-terminal side of the H chain and the entire L chain are bound together by a disulfide bond.
[0097] F(ab')2 is an antibody fragment having a molecular weight of about 100,000 and antigen-binding activity, obtained by digesting the portion below the two disulfide bonds in the hinge region of IgG with the enzyme pepsin, and comprises two Fab regions linked at the hinge position.
[0098] Fab' is an antibody fragment having a molecular weight of about 50,000 and antigen-binding activity, obtained by cleaving the disulfide bond of the hinge region of the above-mentioned F(ab')2.
[0099] Furthermore, the Fab' fragment of the antibody can be produced by inserting a DNA encoding the Fab' fragment into a prokaryotic expression vector or a eukaryotic expression vector and introducing the vector into a prokaryotic or eukaryotic organism to express the Fab'.
[0100] The term "single-chain antibody", "single-chain Fv" or "scFv" refers to a molecule comprising an antibody heavy chain variable domain (or region; VH) and an antibody light chain variable domain (or region; VL) connected by a linker. Such scFv molecules can have the general structure: NH2-VL-linker-VH-COOH or NH2-VH-linker-VL-COOH. Suitable prior art linkers consist of repeated GGGGS amino acid sequences or variants thereof, for example, variants using 1-4 repeats (Holliger et al. (1993), Proc. Natl. Acad. Sci. USA 90: 6444-6448). Other linkers useful in the present disclosure are described by Alfthan et al. (1995), Protein Eng. 8:725-731, Choi et al. (2001), Eur. J. Immunol. 31:94-106, Hu et al. (1996), Cancer Res. 56:3055-3061, Kipriyanov et al. (1999), J. Mol. Biol. 293:41-56, and Roovers et al. (2001), Cancer Immunol.
[0101] The terms "single-domain antibody," "single-domain antibody," or "sdAb" refer to a novel antibody that lacks the CH1 region and light chain of a heavy chain, consisting solely of a single heavy chain variable region, while retaining full antigen-binding activity. Also known as a nanobody, it can selectively bind to a specific antigen, similar to a full antibody. Compared to the 150-160 kDa mass of a full antibody, a single-domain antibody is significantly smaller, approximately 12-15 kDa. The first single-domain antibody was engineered from a camel's heavy chain antibody, known as the "VHH segment."
[0102] The terms "single domain antibody," "heavy chain variable region domain of a heavy chain antibody," "VHH segment," and "nanobody" are used interchangeably. A single domain antibody is a variable region of a heavy chain antibody. Typically, a single domain antibody contains three CDRs and four FRs.
[0103] Single domain antibodies can be derived from any species, including mice, humans, camels, llamas, goats, rabbits and cattle. For example, naturally occurring VHH molecules can be derived from antibodies provided by species of the Camelidae family (e.g., camels, dromedaries, llamas and guanacos). Like complete antibodies, single domain antibodies are capable of selectively binding to specific antigens. Single domain antibodies can contain only the variable domain of an immunoglobulin chain, which has CDR1, CDR2 and CDR3 and a framework region.
[0104] The term "CDR" refers to one of the six hypervariable regions in the variable domain of an antibody that primarily contributes to antigen binding. One of the most commonly used definitions of the six CDRs is provided by Kabat EA et al. (1991) Sequences of proteins of immunological interest. NIH Publication 91-3242). As used herein, the Kabat definition of CDR applies only to CDR1, CDR2, and CDR3 (CDR L1, CDR L2, CDR L3, or L1, L2, L3) of the light chain variable domain, and CDR2 and CDR3 (CDR H2, CDR H3, or H2, H3) of the heavy chain variable domain.
[0105] The term "antibody framework" refers to a portion of a variable domain VL or VH that serves as a scaffold for the antigen binding loops (CDRs) of the variable domain. Essentially, it is a variable domain without CDRs.
[0106] The term "epitope" or "antigenic determinant" refers to the site on an antigen to which an immunoglobulin or antibody specifically binds. An epitope typically comprises at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 consecutive or non-continuous amino acids in a unique spatial conformation. See, for example, Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, G.E. Morris, Ed. (1996).
[0107] The terms "specific binding," "selective binding," "selectively binds," and "specifically binds" refer to the binding of an antibody to an epitope on a predetermined antigen. Typically, the antibody binds with an affinity (KD) of less than about 10-7 M, such as less than about 10-8 M, 10-9 M, or 10-10 M or less.
[0108] The term "nucleic acid" refers to DNA molecules and RNA molecules. Nucleic acid molecules can be single-stranded or double-stranded, but are preferably double-stranded DNA. A nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the coding sequence.
[0109] The term "expression vector" refers to a nucleic acid molecule capable of transporting another nucleic acid connected thereto. In one embodiment, the vector is a "plasmid", which refers to a circular double-stranded DNA loop into which another DNA segment can be connected. In another embodiment, the vector is a viral vector, in which another DNA segment can be connected to a viral genome. The vector disclosed herein can be autonomously replicated in the host cell into which they have been introduced (e.g., bacterial vectors and additional mammalian vectors with a bacterial origin of replication) or can be integrated into the genome of the host cell after being introduced into the host cell, thereby replicating (e.g., non-additional mammalian vectors) with the host genome.
[0110] Methods for producing and purifying antibodies and antigen-binding fragments are well known in the art, such as those described in Chapters 5-8 and 15 of the Cold Spring Harbor Laboratory Manual of Antibody Laboratory Techniques. Antigen-binding fragments can also be prepared using conventional methods. The antibodies or antigen-binding fragments described in the present invention utilize genetic engineering methods to add one or more human FR regions to non-human CDR regions. Human FR germline sequences can be obtained from the ImMunoGeneTics (IMGT) website (http: / / imgt.cines.fr) by comparing the IMGT Human Antibody Variable Region Germline Gene Database with MOE software, or from the Journal of Immunoglobulins, 2001 ISBN 012441351.
[0111] The term "host cell" refers to a cell into which an expression vector has been introduced. Host cells can include bacteria, microorganisms, plants, or animal cells. Bacteria readily transformed include members of the Enterobacteriaceae family, such as strains of Escherichia coli or Salmonella; Bacillaceae, such as Bacillus subtilis; Pneumococcus; Streptococcus and Haemophilus influenzae. Suitable microorganisms include Saccharomyces cerevisiae and Pichia pastoris. Suitable animal host cell lines include CHO (Chinese Hamster Ovary) and NSO cells.
[0112] The engineered antibodies or antigen-binding fragments disclosed herein can be prepared and purified using conventional methods. For example, cDNA sequences encoding heavy and light chains can be cloned and recombined into GS expression vectors. The recombinant immunoglobulin expression vector can be stably transfected into CHO cells. As a more recommended existing technology, mammalian expression systems will result in glycosylation of antibodies, particularly at the highly conserved N-terminal site in the Fc region. Positive clones are expanded in serum-free culture medium in a bioreactor to produce antibodies. The culture fluid that secretes antibodies can be purified using conventional techniques. For example, purification can be performed using an A or G Sepharose FF column containing an adjusted buffer. Non-specifically bound components are washed away. The bound antibodies are then eluted using a pH gradient method, and the antibody fragments are detected by SDS-PAGE and collected. The antibodies can be filtered and concentrated using conventional methods. Soluble mixtures and polymers can also be removed using conventional methods, such as molecular sieves and ion exchange. The resulting product should be immediately frozen, such as at -70°C, or freeze-dried.
[0113] The term "peptide" refers to a compound fragment between amino acids and proteins, which is composed of two or more amino acid molecules connected by peptide bonds. It is a structural and functional fragment of protein. Hormones, enzymes, etc. are essentially peptides.
[0114] The term "sugar" refers to biological macromolecules composed of three elements: C, H, and O, which can be divided into monosaccharides, disaccharides, and polysaccharides.
[0115] The term "fluorescent probe" refers to a class of fluorescent molecules that have characteristic fluorescence in the ultraviolet-visible-near-infrared region, and whose fluorescence properties (excitation and emission wavelengths, intensity, lifetime and polarization, etc.) can sensitively change with the properties of the environment, such as polarity, refractive index, viscosity, etc. They interact non-covalently with nucleic acids (DNA or RNA), proteins or other macromolecular structures to change one or several fluorescent properties, and can be used to study the properties and behavior of macromolecular substances.
[0116] The term "toxic drug" refers to a substance that inhibits or prevents cell function and / or causes cell death or destruction. It includes toxins and other compounds that can be used for tumor treatment.
[0117] The term "alkyl" refers to a saturated aliphatic hydrocarbon group, which is a straight or branched chain group containing 1 to 20 carbon atoms, preferably an alkyl group containing 1 to 12 carbon atoms, more preferably an alkyl group containing 1 to 10 carbon atoms, and most preferably an alkyl group containing 1 to 6 carbon atoms (including 1, 2, 3, 4, 5 or 6 carbon atoms). Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2, 3-Dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl, and various branched-chain isomers thereof. More preferred are lower alkyl groups containing 1 to 6 carbon atoms, non-limiting examples of which include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, and the like. The alkyl group may be substituted or unsubstituted. When substituted, the substituent may be substituted at any available point of attachment. The substituent is preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, and oxo.
[0118] The term "heteroalkyl" refers to an alkyl group containing one or more heteroatoms selected from N, O or S, wherein alkyl is as defined above.
[0119] The term "alkylene" refers to a saturated straight or branched chain aliphatic hydrocarbon group having two residues derived from the same carbon atom or two different carbon atoms of an alkane group by removing two hydrogen atoms, and is a straight or branched chain group containing 1 to 20 carbon atoms, preferably 1 to 12 carbon atoms, and more preferably 1 to 6 carbon atoms (including 1, 2, 3, 4, 5 or 6 carbon atoms). Non-limiting examples of alkylene groups include, but are not limited to, methylene (-CH2-), 1,1-ethylene (-CH(CH3)-), 1,2-ethylene (-CH2CH2)-, 1,1-propylene (-CH(CH2CH3)-), 1,2-propylene (-CH2CH(CH3)-), 1,3-propylene (-CH2CH2CH2-), 1,4-butylene (-CH2CH2CH2CH2-), and 1,5-butylene (-CH2CH2CH2CH2CH2-), and the like. The alkylene group may be substituted or unsubstituted. When substituted, the substituent may be substituted at any available point of attachment. The substituent is preferably independently selected from one or more substituents selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio and oxo.
[0120] The term "alkoxy" refers to -O-(alkyl) and -O-(unsubstituted cycloalkyl), wherein the definition of alkyl or cycloalkyl is as described above. Non-limiting examples of alkoxy include: methoxy, ethoxy, propoxy, butoxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy. Alkoxy can be optionally substituted or unsubstituted, and when substituted, substituents are preferably one or more following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, sulfhydryl, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio.
[0121] The term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent, wherein the cycloalkyl ring contains 3 to 20 carbon atoms, preferably 3 to 12 carbon atoms, more preferably 3 to 10 carbon atoms, and most preferably 3 to 8 carbon atoms (including 3, 4, 5, 6, 7 or 8 carbon atoms). Non-limiting examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, etc.; polycyclic cycloalkyls include spirocyclic, fused ring and bridged ring cycloalkyls.
[0122] The term "heterocyclyl" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent containing 3 to 20 ring atoms, one or more of which is selected from nitrogen, oxygen or S(O) m (wherein m is an integer of 0, 1 or 2) heteroatoms, excluding the ring portion of -OO-, -OS- or -SS-, and the remaining ring atoms are carbon. Preferably, it contains 3 to 12 ring atoms, of which 1 to 4 are heteroatoms (1, 2, 3 or 4 heteroatoms); more preferably, the cycloalkyl ring contains 3 to 10 ring atoms (including 3, 4, 5, 6, 7, 8, 9 or 10 ring atoms). Non-limiting examples of monocyclic heterocyclic groups include pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, etc. Polycyclic heterocyclic groups include spirocyclic, fused ring and bridged heterocyclic groups.
[0123] The term "spiroheterocyclyl" refers to a polycyclic heterocyclic group in which the monocyclic rings of 5 to 20 members share one atom (called a spiro atom), wherein one or more ring atoms are selected from nitrogen, oxygen or S(O) m (wherein m is an integer 0 to 2) heteroatom, and the remaining ring atoms are carbon. It may contain one or more double bonds, but no ring has a completely conjugated π electron system. It is preferably 6 to 14 members, more preferably 7 to 10 members. According to the number of shared spiral atoms between the rings, the spiro heterocyclic group is divided into a monospiro heterocyclic group, a dispiro heterocyclic group or a polyspiro heterocyclic group, preferably a monospiro heterocyclic group and a dispiro heterocyclic group. It is more preferably 4 yuan / 4 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 5 yuan or 5 yuan / 6 yuan monospiro heterocyclic group. Non-limiting examples of spiro heterocyclic groups include:
[0124] The term "fused heterocyclyl" refers to a polycyclic heterocyclic group of 5 to 20 members, wherein each ring in the system shares a pair of adjacent atoms with other rings in the system, one or more rings may contain one or more double bonds, but no ring has a completely conjugated π electron system, wherein one or more ring atoms are selected from nitrogen, oxygen or S(O) m (wherein m is an integer of 0, 1 or 2) heteroatoms, the remaining ring atoms being carbon. Preferably 6 to 14 members, more preferably 7 to 10 members (7, 8, 9 or 10-membered rings). According to the number of constituent rings, it can be divided into a bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclic group, preferably a bicyclic or tricyclic group, more preferably a 5-membered / 5-membered or 5-membered / 6-membered bicyclic fused heterocyclic group. Non-limiting examples of fused heterocyclic groups include:
[0125] The term "bridged heterocyclyl" refers to a 5- to 14-membered polycyclic heterocyclic group in which any two rings share two atoms that are not directly connected, which may contain one or more double bonds but no ring has a completely conjugated π electron system, wherein one or more ring atoms are selected from nitrogen, oxygen or S(O)m (wherein m is an integer of 0, 1 or 2) heteroatoms, the remaining ring atoms being carbon. Preferably, it is 6 to 14 members, more preferably 7 to 10 members (7-membered, 8-membered, 9-membered or 10-membered ring). Depending on the number of constituent rings, it can be classified as a bicyclic, tricyclic, tetracyclic or polycyclic bridged heterocyclic group, preferably a bicyclic, tricyclic or tetracyclic group, more preferably a bicyclic or tricyclic group. Non-limiting examples of bridged heterocyclic groups include:
[0126] The heterocyclyl ring may be fused to an aryl, heteroaryl or cycloalkyl ring, wherein the ring attached to the parent structure is a heterocyclyl, non-limiting examples of which include:
[0127] wait.
[0128] The heterocyclic group may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, and oxo.
[0129] The term "aryl" refers to a 6- to 14-membered all-carbon monocyclic or fused polycyclic (i.e., rings sharing adjacent pairs of carbon atoms) group having a conjugated π electron system, preferably 6- to 10-membered (6-, 7-, 8-, 9-, or 10-membered) group, such as phenyl and naphthyl, preferably phenyl. The aryl ring may be fused to a heteroaryl, heterocyclyl, or cycloalkyl ring, wherein the ring attached to the parent structure is the aryl ring, non-limiting examples of which include:
[0130] The aryl group may be substituted or unsubstituted. When substituted, the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio.
[0131] The term "heteroaryl" refers to a heteroaromatic system containing 1 to 4 heteroatoms (1, 2, 3 or 4 heteroatoms) and 5 to 14 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur and nitrogen. The heteroaryl group is preferably 5 to 10-membered (5-membered, 6-membered, 7-membered, 8-membered, 9-membered or 10-membered heteroaryl), more preferably 5-membered or 6-membered, such as furyl, thienyl, pyridyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, imidazolyl, tetrazolyl and the like. The heteroaryl ring may be fused to an aryl, heterocyclyl or cycloalkyl ring, wherein the ring connected to the parent structure is a heteroaryl ring, non-limiting examples of which include:
[0132] The heteroaryl group may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio.
[0133] The term "amino-protecting group" is used to protect the amino group with an easily removable group in order to maintain the amino group intact while reacting other parts of the molecule. Non-limiting examples include 9-fluorenylmethyloxycarbonyl, tert-butyloxycarbonyl, acetyl, benzyl, allyl, and p-methoxybenzyl. These groups may optionally be substituted with 1-3 substituents (1, 2, or 3 substituents) selected from halogen, alkoxy, or nitro. The amino-protecting group is preferably 9-fluorenylmethyloxycarbonyl.
[0134] The term "haloalkyl" refers to an alkyl group substituted with one or more halogens, wherein alkyl is as defined above.
[0135] The term "deuterated alkyl" refers to an alkyl group substituted with one or more deuterium atoms, wherein alkyl is as defined above.
[0136] The term "hydroxyalkyl" refers to an alkyl group substituted with one or more hydroxy groups, wherein alkyl is as defined above.
[0137] The term "hydroxy" refers to an -OH group.
[0138] The term "halogen" refers to fluorine, chlorine, bromine or iodine.
[0139] The term "amino" refers to -NH2.
[0140] The term "nitro" refers to -NO2.
[0141] The term "cyano" refers to -CN.
[0142] The term "amido" refers to -C(O)N(alkyl) or (cycloalkyl), wherein alkyl and cycloalkyl are as defined above.
[0143] The term "carboxylate" refers to -C(O)O(alkyl) or (cycloalkyl), wherein alkyl and cycloalkyl are as defined above.
[0144] The present disclosure also includes various deuterated forms of compounds of formula (I). Each available hydrogen atom connected to a carbon atom can be independently replaced by a deuterium atom. Those skilled in the art can synthesize deuterated forms of compounds of formula (I) with reference to relevant literature. When preparing deuterated forms of compounds of formula (I), commercially available deuterated starting materials can be used, or they can use conventional techniques to synthesize deuterated reagents, which include but are not limited to deuterated borane, trideuteroborane tetrahydrofuran solution, deuterated lithium aluminum hydride, deuterated iodoethane and deuterated iodomethane etc.
[0145] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and where it does not. For example, "a heterocyclic group optionally substituted with an alkyl group" means that an alkyl group may but need not be present, and that the description includes instances where the heterocyclic group is substituted with an alkyl group and instances where the heterocyclic group is not substituted with an alkyl group.
[0146] "Substituted" means that one or more hydrogen atoms, preferably up to 5, more preferably 1, 2 or 3 hydrogen atoms in a group are replaced independently of one another by a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and those skilled in the art can determine (by experiment or theory) possible or impossible substitutions without undue effort. For example, an amino or hydroxyl group with free hydrogen may be unstable when combined with a carbon atom with an unsaturated (e.g., olefinic) bond.
[0147] The term "pharmaceutical composition" refers to a mixture containing one or more compounds described herein, or their physiologically / pharmaceutically acceptable salts or prodrugs, together with other chemical components, as well as other components such as physiologically / pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitating absorption of the active ingredient and thereby exerting its biological activity.
[0148] The term "pharmaceutically acceptable salt" or "pharmaceutically acceptable salt" refers to a salt of the antibody-drug conjugates of the present disclosure, or a salt of a compound described in the present disclosure. Such salts are safe and effective when used in mammals and have the desired biological activity. The antibody-drug conjugates of the present disclosure contain at least one amino group and can therefore form salts with acids. Non-limiting examples of pharmaceutically acceptable salts include hydrochloride, hydrobromide, hydroiodide, sulfate, bisulfate, citrate, acetate, succinate, ascorbate, oxalate, nitrate, sorbate, hydrogen phosphate, dihydrogen phosphate, salicylate, hydrogen citrate, tartrate, maleate, fumarate, formate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, and p-toluenesulfonate.
[0149] The term "solvate" refers to a pharmaceutically acceptable solvate formed between the antibody-drug conjugate of the present disclosure and one or more solvent molecules. Non-limiting examples of solvent molecules include water, ethanol, acetonitrile, isopropanol, DMSO, and ethyl acetate.
[0150] The term "drug loading" refers to the average amount of cytotoxic drug loaded on each antibody in the formula (I) molecule, and can also be expressed as the ratio of the amount of drug to the amount of antibody. The drug loading range can be 0-12, preferably 1-10, cytotoxic drugs (D) attached to each antibody (Pc). In the embodiments of the present disclosure, the drug loading is expressed as n, which can also be called the DAR value, and exemplary values are 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10. The average amount of drug per ADC molecule after the coupling reaction can be identified using conventional methods such as UV / visible spectroscopy, mass spectrometry, ELISA assays, and HPLC characterization.
[0151] In one embodiment of the present disclosure, the cytotoxic drug is coupled to the N-terminal amino group and / or the ε-amino group of a lysine residue of an antibody via a linker. Generally, the number of drug molecules that can be coupled to the antibody in the coupling reaction will be less than the theoretical maximum value.
[0152] The loading capacity of the antibody cytotoxic drug conjugate can be controlled by the following non-limiting methods, including:
[0153] (1) Control the molar ratio of the linker and the monoclonal antibody,
[0154] (2) Control reaction time and temperature,
[0155] (3) Select different reaction reagents.
[0156] The preparation of conventional pharmaceutical compositions can be found in the Chinese Pharmacopoeia.
[0157] The term "carrier" as used in the context of the present invention refers to a system that can alter the way a drug enters the human body and its distribution within the body, control the rate of drug release, and deliver the drug to a targeted organ. Drug carrier release and targeting systems can reduce drug degradation and loss, reduce side effects, and improve bioavailability. For example, polymeric surfactants that can be used as carriers can self-assemble to form various forms of aggregates due to their unique amphiphilic structure, preferably micelles, microemulsions, gels, liquid crystals, vesicles, and the like. These aggregates have the ability to encapsulate drug molecules while also having good membrane permeability, making them excellent drug carriers.
[0158] The term "excipient" refers to any additive in a pharmaceutical preparation other than the main drug, also known as an adjuvant. Examples include binders, fillers, disintegrants, and lubricants in tablets; the base component of semisolid ointments and creams; and preservatives, antioxidants, flavoring agents, fragrances, cosolvents, emulsifiers, solubilizers, osmotic pressure regulators, and colorants in liquid preparations.
[0159] The term "diluent," also known as filler, primarily increases the weight and volume of a tablet. The addition of a diluent not only maintains a certain volume but also reduces dosage variations of the main ingredient and improves the drug's compressibility. When the tablet contains an oily component, an absorbent is added to absorb the oil and maintain a "dry" state, facilitating tablet production. Examples include starch, lactose, inorganic calcium salts, and microcrystalline cellulose.
[0160] The pharmaceutical composition may be in the form of a sterile injectable aqueous solution. Acceptable vehicles and solvents that may be used include water, Ringer's solution, and isotonic sodium chloride solution. The sterile injectable formulation may be a sterile injectable oil-in-water microemulsion in which the active ingredient is dissolved in an oil phase. For example, the active ingredient is dissolved in a mixture of soybean oil and lecithin. The oil solution is then added to a mixture of water and glycerol to form a microemulsion. The injection solution or microemulsion may be injected into the patient's bloodstream via local bolus injection. Alternatively, the solution or microemulsion may be administered in a manner that maintains a constant circulating concentration of the disclosed compound. To maintain such a constant concentration, a continuous intravenous drug delivery device may be used. An example of such a device is the Deltec CADD-PLUS™ 5400 intravenous pump.
[0161] Pharmaceutical compositions can be in the form of sterile injectable aqueous or oily suspensions for intramuscular and subcutaneous administration. Such suspensions can be formulated using suitable dispersants or wetting agents and suspending agents as described above, according to known techniques. Sterile injectable formulations can also be sterile injectable solutions or suspensions prepared in a nontoxic, parenterally acceptable diluent or solvent, such as a solution prepared in 1,3-butanediol. Furthermore, sterile fixed oils can conveniently be used as solvents or suspending media. For this purpose, any blended fixed oil, including synthetic mono- or diglycerides, can be used. Furthermore, fatty acids, such as oleic acid, can also be used to prepare injectable formulations.
[0162] The present disclosure relates to a class of cleavable linkers with specific structures and active substances with specific structures, as well as antibody-drug conjugates (ADCs) composed of the linkers, active substances, and antibodies. These ADCs are complexes formed by linking a toxic substance to an antibody via a spacer. These antibody-drug conjugates (ADCs) degrade in vivo to release the active molecule, thereby exerting anti-tumor effects. BRIEF DESCRIPTION OF THE DRAWINGS
[0163] Figure 1: Activity test results of recombinant human SEZ6 protein.
[0164] FIG2A : Detection results of human SEZ6 expression in stably transfected cell lines; FIG2B : Detection results of monkey SEZ6 expression in stably transfected cell lines.
[0165] FIG3A : The results of the binding activity detection of the mouse chimeric antibody to human SEZ6 on the cell membrane; FIG3B : The results of the binding activity detection of the mouse chimeric antibody to monkey SEZ6 on the cell membrane.
[0166] Figure 4: Results of mouse chimeric antibody internalization and immunotoxin killing activity assays.
[0167] Figure 5: Binding activity test results of humanized antibodies to human cell membrane proteins.
[0168] FIG6A : The results of internalization and immunotoxin killing activity detection of humanized antibodies on H69 cells; FIG6B : The results of internalization and immunotoxin killing activity detection of humanized antibodies on H82 cells.
[0169] FIG7A : The results of the binding activity detection of the chimeric Nanobody to human SEZ6 on the cell membrane; FIG7B : The results of the binding activity detection of the chimeric Nanobody to monkey SEZ6 on the cell membrane.
[0170] Figure 8: Results of internalization and immunotoxin killing activity assay of chimeric nanobodies on H69 cells.
[0171] Figure 9: Binding activity test results of humanized nanobodies to human SEZ6 protein on the cell membrane.
[0172] Figure 10: Results of internalization and immunotoxin killing activity assay of humanized nanobodies on H69 cells.
[0173] Figure 11: Binding activity test results of PR3178 and PR0071 against SEZ6 homologous proteins.
[0174] FIG12 : Results of affinity epitope identification of PR3178 and PR0071 for SEZ6.
[0175] FIG13A shows the inhibitory activity of PR3178-9106 and PR0071-9106 in H69 cells in vitro; FIG13B shows the inhibitory activity of PR3178-9106 and PR0071-9106 in H82 cells in vitro.
[0176] Figure 14: Anti-tumor activity of PR3178-9106 and PR0071-9106 in the H69 xenograft model.
[0177] Figure 15: Single-dose pharmacokinetic evaluation of PR3178-9106 and PR0071-9106 in SCID mice. DETAILED DESCRIPTION
[0178] The following embodiments are used for further description, but these embodiments are not intended to limit the scope of the present invention.
[0179] Experimental procedures in the Examples or Test Examples where specific conditions are not specified were generally performed under conventional conditions or according to the conditions recommended by the raw material or commercial manufacturer. See Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory; and Current Methods in Molecular Biology, Ausubel et al., Greene Publishing Associates, Wiley Interscience, NY. Reagents where the source is not specified were commercially available.
[0180] Example 1. Activity detection of recombinant SEZ6 protein
[0181] The recombinant human SEZ6-Fc fusion protein is a human IgG1 Fc tag fused to the C-terminus of the human SEZ6 protein ECD region (see GenBank database, accession number: NP_849191, SEQ ID NO: 1). The recombinant human SEZ6-His6 protein is a polyhistidine tag His6 fused to the C-terminus of the human SEZ6 extracellular domain (ECD) (see GenBank database, accession number: NP_849191). The recombinant monkey SEZ6-His6 protein is a His tag fused to the C-terminus of the monkey SEZ6 ECD region (see GenBank database, accession number: XP_005583333.2, SEQ ID NO: 2). The recombinant mouse SEZ6-His6 protein is a His tag fused to the C-terminus of the mouse SEZ6 ECD region (positions 1-922) (see GenBank database, accession number: NP_067261, SEQ ID NO: 3). The extracellular domain sequence is underlined.
[0182] Table 1. Amino acid sequences of proteins used for immunization or screening
[0183] To verify the immunoreactivity of the recombinant protein, ELISA (enzyme-linked immunosorbent assay) was performed. Specifically, recombinant human SEZ6-His6 protein was diluted to 1 μg / mL in PBS and added to an ELISA microplate (100 μL per well) for overnight incubation at 4°C. ELISA blocking buffer (PBS phosphate buffer containing 1% BSA (w / v), pH 7.4) was added and blocked at 37°C for 2 hours. Then, serially diluted anti-SEZ6 detection antibody hSC200 (hSC17.200, heavy chain SEQ ID NO: 6, light chain SEQ ID NO: 7) was added and incubated at 37°C for 1 hour. The plate was washed 2-3 times with plate washer buffer. A secondary antibody conjugated to horseradish peroxidase (HRP) was added and incubated at 37°C for 1 hour. The plate was washed 2-3 times with plate washer buffer. TMB substrate (100 μL per well) was added and incubated at room temperature for 15 minutes. Then, 50 μL of stop buffer (2 M HCl) was added to each well. The OD450nm value was read using an ELISA plate reader (SpectraMax M5e). The results are shown in Figure 1 : The recombinant human SEZ6-His6 protein was able to bind to the SEZ6 antibody hSC200 with high affinity and could be used for subsequent in vivo protein immunization.
[0184] WO2019232241 (AbbVie Stemcentrx LLC) discloses the hSC200 sequence as follows:
[0185] Example 2. Establishment of a stable cell line expressing recombinant human SEZ6
[0186] In order to screen candidate antibody molecules with affinity for membrane proteins, an overexpression cell line was constructed for the screening process. Specifically, CHO-K1 cells were transfected with a plasmid encoding recombinant human SEZ6 protein or a plasmid encoding cynomolgus monkey SEZ6 protein, and cell lines stably expressing recombinant human or cynomolgus monkey SEZ6 protein were obtained through screening. The nucleotide sequence encoding the human or cynomolgus monkey SEZ6 protein was cloned and connected to a lentiviral expression vector to prepare a plasmid. The CHO-K1 cell line was transfected using a well-known lentiviral transfection method in the industry, selectively cultured for two weeks using F-12 medium containing Puromycin (purchased from Gibco), and subcloned in a 96-well culture plate using the limiting dilution method. The cells were then cultured in a cell culture incubator. After two weeks, the selected single clones were detected and screened by flow cytometry. The results in Figure 2 show that the cell line can stably express human SEZ6 or monkey SEZ6 at high levels and can be used in subsequent antibody screening processes.
[0187] Example 3. Immunization of mice with recombinant SEZ6 protein to obtain mouse anti-SEZ6 monoclonal antibodies
[0188] To screen for antibodies that specifically bind to human and monkey SEZ6 membrane proteins, this experiment used full-length human SEZ6 expression plasmids, recombinant human SEZ6-Fc, and human SEZ6-His6 proteins as immunogens to immunize 6-8 week-old Balb / c and SJL / J mice. Recombinant human SEZ6-His6 was used as an immunogen to immunize Balb / c and SJL / J mice. The initial immunization dose was 50 μg per mouse. Two weeks after the initial immunization, booster immunizations were administered at a dose of 25 μg per mouse, with two weeks between booster immunizations.
[0189] Serum samples were collected one week after each booster immunization, and the antibody titer in the mouse serum was detected by ELISA. The plate was coated with 1μg / mL recombinant human SEZ6-His6, incubated at 4°C overnight, blocked with PBST buffer containing 1% BSA for 1 hour, and washed 3 times. The mouse serum was diluted 10-fold in the blocking buffer starting at 1:100, incubated at 37°C for 1 hour, washed 3 times, and incubated with the secondary antibody (HRP labeled) against mouse IgG-Fc for 1 hour. Washed 3 times with PBST, 100μL TMB substrate was added to each well, and the reaction was terminated with 2M HCl after 15 minutes to measure the absorbance at 450nm. The sera of immune mice have different degrees of binding to the immunogen, and the highest dilution of the serum is 1:10. 5 When the antigen-antibody reaction is still present.
[0190] The last immunization was intraperitoneal injection of 25 μg recombinant human SEZ6-His6 protein. Five days later, the mice were killed and the spleens were removed. Splenocytes were collected by grinding. NH4OH at a final concentration of 1% (w / w) was added to lyse the red blood cells mixed in the spleen cells to obtain a spleen cell suspension. The cells were centrifuged and washed three times at 1000 rpm. Mouse spleen cells were mixed with mouse myeloma cells SP2 / 0 at a live cell ratio of 5:1, and cell fusion was performed using a high-efficiency electrofusion method. The fused cells were diluted with DMEM medium containing 20% fetal bovine serum and 1×HAT (w / w) to a 96-well cell culture plate, with 200 μL per well for a total of 1 x 10 5 Cells were cultured in a 37°C incubator with 5% (v / v) CO₂. After 14 days, confluent cells were screened using ELISA and FACS. Positive clones with an OD450nm >1.0 and a FACS-positive cell ratio greater than 20% were expanded into 24-well plates and further cultured at 37°C with 5% (v / v) CO₂ in DMEM supplemented with 10% (w / w) HT fetal bovine serum. Three days later, the supernatant from the 24-well plate was centrifuged and collected. Binding activity to the SEZ6 protein and SEZ6-positive cells was determined by ELISA and FACS. After two rounds of monoclonal cloning, positive clones were sequenced. The variable region sequences of the mouse antibodies are shown in Table 2.
[0191] Table 2. Mouse anti-SEZ6 antibody sequences
[0192] Recombinant chimeric antibodies were obtained by replacing the constant region of a mouse monoclonal antibody. The nucleotide sequence encoding the mouse monoclonal antibody variable region was then cloned into a pTT5 vector containing sequences encoding the human heavy and light chain constant regions (human IgG1, kappa). The gene sequence was synthesized and transfected into HEK293 cells. After 5 days, the cells were centrifuged to collect and filter the cell culture fluid. The harvested cell culture supernatant was loaded onto a Protein A column (MabSelect SuRe, GE). The bound antibody was eluted with glycine, the eluate was neutralized with 1M Tris, and the buffer was replaced with PBS to obtain the chimeric antibody.
[0193] Example 4. Immunization of camels with recombinant SEZ6 protein to obtain anti-SEZ6 nanobodies
[0194] To screen for more antibodies that specifically bind to human and monkey SEZ6 membrane proteins, this experiment added immunized camels. The specific method was to immunize two healthy camels with recombinant human SEZ6-Fc. After 4-5 immunizations, 200 ml of peripheral blood was collected from each camel and PBMCs were isolated. RNA was extracted with TriZol, reverse transcribed to prepare cDNA, and then PCR amplified the antibody gene. After enzyme digestion, ligation, and transformation, a VHH phage display library (library capacity 1.2×10 9 Random sequencing results showed that the positive rate of antibody gene insertion reached 96%.
[0195] A previously constructed immune antibody library was screened using biotinylated recombinant human SEZ6-His6 protein. Affinity panning was performed for 3-5 rounds. Single clones were randomly selected for phage preparation and assayed by phage ELISA. Positive clones were selected for sequencing and sequence analysis. Clones with unique sequences were used to construct VHH-hFc expression vectors, which were transiently expressed in 293 cells and analyzed by ELISA and FACS. The amino acid sequences of some VHH antibodies are shown in Table 3.
[0196] Table 3. Sequences of camel-derived anti-SEZ6 antibodies
[0197] Example 5. Humanization of antibodies
[0198] In order to reduce the immune response of non-human species to the human body, it is necessary to humanize mouse and camel antibodies. The specific implementation method is as follows: for humanized antibodies, after predicting the structure of mouse monoclonal antibodies by homology modeling, the mouse antibody CDR is chimerized into a suitable human GermLine framework (Bioinformation.2014;10(4):180–186;Methods Mol Biol.2019;1904:213-230), and then reverse mutations are introduced at sites that may affect antibody-antigen binding. Finally, the nucleotide sequence encoding the variable region of the humanized monoclonal antibody is cloned into the pTT5 vector containing the protein sequence encoding the human heavy and light chain constant regions (Human IgG1, kappa), and transfected into HEK293 cells using a similar method as mentioned above to produce humanized antibodies.
[0199] The sequence of the human IgG1 constant region is as follows: (SEQ ID NO: 33)
[0200] The Kappa constant region sequence is as follows: (SEQ ID NO: 59)
[0201] The variable region frameworks used to humanize murine antibodies are shown in Table 4, the humanized antibody variable region sequences are shown in Table 5, the heavy chain CDRs (HCDR1 / HCDR2 / HCDR3) and light chain CDRs (LCDR1 / LCDR2 / LCDR3) are shown in Table 6, and the full-length amino acid sequences of the humanized antibodies are shown in Table 7. PR3178 is a humanized version of cAb3009, PR3121 and PR3123 are humanized versions of cAb3014, and PR3132 is a humanized version of cAb3056.
[0202] Table 4. Framework selection for humanized antibody variable regions from mouse antibodies
[0203] Table 5. Variable region sequences of humanized anti-SEZ6 antibodies
[0204] Table 6. CDR sequences of humanized anti-SEZ6 antibodies (Kabat numbering system)
[0205] Table 7. Full-length amino acid sequences of heavy and light chains of humanized antibodies
[0206] The variable region framework used for the humanized antibodies of Nanobodies is shown in Table 8, the humanized antibody variable region sequence is shown in Table 9, the heavy chain CDR (HCDR1 / HCDR2 / HCDR3) is shown in Table 10, and the humanized antibody amino acid sequence fused to the human IgG1-Fc fragment is shown in Table 11. Among them, PR0069 is a humanized antibody of cAb025, and PR0071 is a humanized antibody of cAb314.
[0207] Table 8. Framework selection for humanized anti-SEZ6 nanobody variable regions
[0208] Table 9. Variable region sequences of humanized anti-SEZ6 nanobodies
[0209] Table 10. CDR sequences of humanized anti-SEZ6 nanobodies (Kabat numbering system)
[0210] Table 11. Amino acid sequence of humanized anti-SEZ6 nanobody-Fc protein
[0211] Example 6 SEC-6 Binding Activity of Anti-SEC-6 Antibodies on Cells
[0212] In order to screen chimeric or humanized antibodies that can bind to human and monkey SEZ6 membrane proteins with high affinity, the fluorescence signal of the antibody bound to the cell surface was detected and the binding strength of the antibody was evaluated according to the intensity of the fluorescence signal. 5 The cells were incubated at 4°C for 1 hour, excess antibody was washed off, and a mouse Alexa Flour 647-labeled anti-human Fc antibody was added. The cells were incubated at 4°C for 30 minutes. Excess antibody was washed off and the cells were resuspended in 200 μL of 1% BSA / PBS buffer. Cell surface fluorescence signals were read using a Thermo Attune NxT flow cytometer. Table 12 shows the binding characteristics of the mouse chimeric anti-antibody (Figure 3), Table 13 shows the binding characteristics of the mouse humanized antibody (Figure 5), Table 14 shows the binding characteristics of the nano-chimeric antibody (Figure 7), and Table 15 shows the affinity characteristics of the nano-humanized antibody (Figure 9). The results show that the candidate antibodies have SEZ6 membrane protein binding activity similar to that of hSC200.
[0213] Table 12. In vitro characterization of murine SEZ6 chimeric antibodies
[0214] Table 13. In vitro characterization of humanized anti-SEZ6 murine antibodies
[0215] Table 14. In vitro characterization of camel-derived SEZ6 chimeric antibodies
[0216] Table 15. In vitro characterization of humanized anti-SEZ6 camelid antibodies
[0217] Example 7 Determination of in vitro cellular internalization activity of anti-SEZ6 antibodies
[0218] To evaluate the endocytic activity of antibodies, the DT3C antibody internalization activity evaluation system was used. DT3C is a recombinantly expressed fusion protein with a molecular weight of 70 kDa. It is composed of the fusion of Fragment A of diphtheria toxin (toxin only) and the 3C fragment of group G Streptococcus (IgG-binding portion). This protein has a high affinity for the IgG portion of the antibody and enters the cell together with the antibody during endocytosis. Under the action of intracellular furin, DT is released, which is toxic. DT inhibits EF2-ADP ribosylation activity, blocks protein translation, and ultimately causes cell death. By using this system, the cell-killing effects caused by antibody internalization and immunotoxin production can be simultaneously observed (Yamaguchi, M., Hama, H., et al., Biochemical and Biophysical Research Communications 454 (2014) 600-603).
[0219] The internalization and immunotoxin activity of DT3C are evaluated as follows: sterile-filtered DT3C and the chimeric antibody to be tested (DT3C at a molar concentration twice that of the antibody) are mixed at a 1:1 ratio, incubated at 37°C for 30 minutes, then serially diluted with complete medium and added to cells (H69 or H82) (3000 cells / well). The cells are incubated at 37°C in a 5% CO2 incubator for 6 days. CellTiter-Glo is added, incubated at room temperature in the dark for 10 minutes, and chemiluminescence is measured on a PerkinElmer ELISA. As shown in Figure 4, the murine chimeric antibodies cAb3009, cAb3014, and cAb3056 exhibited stronger internalization and immunotoxin activity than the control molecule hSC200. In addition, the endocytic activity of a series of chimeric antibodies with similar sequences, cAb3003, cAb3005, cAb3006, and cAb3009, were significantly better than that of the control molecule hSC200: the general formulas of CDRH1, CHDRH2, and CDRH3 in this series of sequences are XYEMH, GIDPEXXNTVYNQKFKX, and GDWYFDX; the general formulas of CDRL1, CDRL2, and CDRL3 are KSSQSLLNSRTRENYLA, WASTRXX, and XQSYNLFT.
[0220] Table 16. In vitro characterization of humanized anti-SEZ6 murine antibodies
[0221] Table 17. In vitro characterization of camel-derived SEZ6 chimeric antibodies
[0222] Table 18. In vitro characterization of humanized anti-SEZ6 camelid antibodies
[0223] As shown in Table 16 and Figure 6 , humanized anti-SEZ6 murine antibodies PR3178, PR3121, PR3123, and PR3132 exhibited internalization and immunotoxin activity comparable to or slightly stronger than the control molecule hSC200. As shown in Table 17 and Figure 8 , camelid-derived chimeric antibodies cAb025 and cAb314 exhibited stronger internalization and immunotoxin activity than the control molecule hSC200. As shown in Table 18 and Figure 10 , humanized anti-SEZ6 camelid antibodies PR0069 and PR0071 exhibited stronger internalization and immunotoxin activity than the control molecule hSC200.
[0224] Example 8 Affinity detection of anti-SEZ6 antibodies to SEZ6 homologous family members SEZ6L and SEZ6L2
[0225] To identify antibodies with specific affinity for SEZ6, ELISA was used to test their binding to SEZ6 homologous proteins. Specifically, recombinant human SEZ6-Fc fusion protein, SEZ6L-Fc protein, and SEZ6L2-Fc were diluted to 1 μg / mL in PBS and added to 100 μL per well of an ELISA microplate. The plates were incubated overnight at 4°C. ELISA blocking buffer (PBS phosphate buffer containing 1% BSA (w / v), pH 7.4) was added and blocked at 37°C for 2 hours. Detection antibodies were then added at 10 nM, incubated at 37°C for 1 hour, and washed two to three times with plate washer buffer. A horseradish peroxidase (HRP)-conjugated secondary antibody was added, incubated at 37°C for 1 hour, and washed two to three times with plate washer buffer. TMB substrate (100 μL per well) was added and incubated at room temperature for 15 minutes. Then, 50 μL of stop buffer (2 M HCl) was added to each well. The OD450nm value was read using an ELISA plate reader (SpectraMax M5e).
[0226] The results are shown in FIG11 . Both PR3178 and PR0071 bind to the SEZ6 protein, but do not bind to the SEZ6L protein and the SEZ6L2 protein, indicating that PR3178 and PR0071 have good affinity and specificity.
[0227] Example 9 Identification of the affinity epitope of anti-SEZ6 antibodies to SEZ6
[0228] Antibody endocytosis activity correlates with antigen-affinity epitopes. This assay uses ELISA to identify the antigen-affinity epitopes of antibodies. Specifically, recombinant human SEZ6-SUSHI1, SEZ6L-SUSHI2, and SEZ6-N1 proteins were diluted to 1 μg / mL in PBS and added to 100 μL per well of an ELISA microplate. The plates were incubated overnight at 4°C. ELISA blocking buffer (PBS phosphate buffer containing 1% BSA (w / v), pH 7.4) was added and blocked at 37°C for 2 hours. Detection antibodies were then added at 10 nM, incubated at 37°C for 1 hour, and washed two to three times with plate washer. A secondary antibody conjugated to horseradish peroxidase (HRP) was added and incubated at 37°C for 1 hour. The plates were washed two to three times with plate washer. TMB substrate (100 μL per well) was added and incubated at room temperature for 15 minutes. Then, 50 μL of stop solution (2 M HCl) was added to each well. The OD450nm value was read using an ELISA plate reader (SpectraMax M5e).
[0229] The results are shown in Figure 12. PR3178 binds to the SUSHI4 domain of the SEZ6 protein, while PR0071 binds to a separate domain of SEZ6 other than SUSHI1, SUSHI4, and N1. The screened antibody molecules all have unique affinity epitopes and exhibit superior endocytic activity.
[0230] Example 10 Evaluation of the Kinetics of Interaction between Antibodies and SEZ6 Using Surface Plasmon Resonance (SPR)
[0231] The affinity activity of PR3178 and PR0071 antibodies was detected by SPR using a BIAcore 8K (Cityva) system. The protein A sensor chip and related reagents were purchased from Cytiva. Antibodies PR3178, PR0071, and a control antibody were diluted to 1 μg / ml in HBS-EP+ buffer. The flow rate was set at 10 μl / min, and the capture antibody was maintained at 200 RU. His-tagged SEZ6 antigen was diluted in HBS-EP+ buffer to a concentration gradient of 0 nM, 3.125 nM, 6.25 nM, 12.5 nM (duplicate), 25 nM, 50 nM, 100 nM, and 200 nM. Samples were analyzed at a flow rate of 30 μl / min. Association time was 120 s, and dissociation time was 900 s. Regeneration was then performed using pH 1.5 Gly-HCl buffer at a flow rate of 30 μl / min for 30 seconds. The response signal was plotted against the analysis time on the horizontal axis and the response value on the vertical axis. The data were fitted using BIAcore 8K analysis software using a 1:1 Langmuir binding model to determine kinetic constants such as the association rate constant (Ka), dissociation rate constant (Kd), and dissociation equilibrium constant (KD). The results showed that PR3178 and PR0071 molecules bound to both human and cynomolgus macaque antigens with greater affinity than hSC200.
[0232] Table 19. Binding kinetic parameters of anti-SEZ6 antibodies
[0233] Example 11 PR3178 and PR0071 coupled to small molecule toxins
[0234] To target the small molecule toxin 9106 to tumors, this experiment involved conjugating the antibodies PR3178 and PR0071 to the small molecule toxin 9106. The specific experiment was as follows: At 37°C, a solution of tris(2-carboxyethyl)phosphine hydrochloride (TCEP-HCl) in water (10 mM, 75.4 μL, 753.5 nmol) was added to a solution of the antibody in PBS buffer (0.05 M PBS buffer, pH 6.5; 10.0 mg / mL, 5.0 mL, 342.5 nmol). The mixture was placed in a shaker water bath and incubated at 37°C for 3 hours. The reaction was then stopped. The reaction solution was cooled to 25°C in a water bath.
[0235] Compound 9106 (3.7 mg, 3424.6 nmol) prepared according to WO2020063676A1 was dissolved in 250 μL of dimethyl sulfoxide, added to the above reaction solution, placed in a water bath shaker, and oscillated at 25 ° C for 3 hours to stop the reaction. The reaction solution was desalted with HiPrep 26 / 10 (buffer: PBS pH 7.2-7.4, flow rate 10 mL / min), concentrated using an ultrafiltration tube, and PBS buffer solutions of PR3178-9106 and PR0071-9106 were obtained (PR3178-9106 concentration was 1.0 mg / mL, 26 mg; PR0071-9106 concentration was 2.0 mg / mL, 20 mg), and stored refrigerated at 4 ° C. The anti-SEZ6 detection antibody hSC200 (hSC17.200, heavy chain SEQ ID NO: 6, light chain SEQ ID NO: 7) was conjugated to 9106 in the same manner as above.
[0236] The structures of the antibody drug conjugates PR3178-9106 and PR0071-9106 were obtained as follows. The drug loading was calculated by RP-HPLC. The DAR values of PR3178-9106 and PR0071-9106 were n=4.1 and n=3.6, respectively.
[0237] Example 12 Determination of ADC activity in inhibiting tumor cell line proliferation in vitro
[0238] To test the in vitro anti-tumor activity of the conjugated ADC molecules, the in vitro activity of the ADC was reflected by inhibiting the growth of tumor cell lines. Specifically, H69 and H82 cells were grown overnight in 96-well culture plates at a density of 3000 per well. The next day, equal volumes of serially diluted toxin-conjugated drugs were added. After 5 days, cell viability was determined using the CellTiter-Glo Luminescent Cell Viability Assay Kit (Promega) as described in the manufacturer's protocol. Cell viability was assessed as a percentage of untreated control cells. As shown in Figure 13, the ADC drug had good killing activity on the H69 and H82 tumor cell lines.
[0239] Table 20. Cytotoxicity of ADCs in cell lines with different expression levels
[0240] Example 13 Evaluation of ADC anti-tumor activity in vivo
[0241] To test the in vivo anti-tumor activity of ADC molecules, an H69 xenograft tumor model was used to measure tumor growth and size changes to reflect the anti-tumor activity of ADCs. Specifically, to generate xenografts, SCID mice were subcutaneously inoculated with 5x10^6 H69 cells / 0.2ml (PBS+gel) on the right back, and the average tumor volume reached 128mm. 3 The mice were divided into 5 groups according to tumor volume and body weight, with 6 mice in each group. Drugs were administered on the day of grouping, with two intraperitoneal injections on Day 0 and Day 7. Tumor volume and body weight were measured twice a week and the data were recorded.
[0242] Tumor volume V = 1 / 2 × a × b 2 , where a and b represent length and width, respectively. Relative tumor growth rate (T / C) (%) = (T - T0) / (C - C0) × 100, where T and C represent the tumor volumes of the treatment and control groups at the end of the experiment; T0 and C0 represent the tumor volumes at the start of the experiment. Tumor inhibition index (TGI) (%) = 1 - T / C (%). As described above, a human IgG control antibody was used as a negative control. TGI represents the maximum tumor growth inhibition during the experiment.
[0243] The study results are shown in Figure 14 and Table 21. The ADC has significant anti-tumor activity against the growth of H69 xenograft tumors at equimolar dose levels.
[0244] Table 21. In vivo anti-tumor activity of anti-SEZ6 ADC
[0245] Note: vs. control group hIgG1: *p<0.05, **p<0.001, ***p<0.0001
[0246] Example 14 Determination of Plasma Concentration of Toxin-Conjugated Drugs
[0247] To characterize the pharmacokinetic characteristics of the ADC in mice, serum ADC concentrations were determined by ELISA after a single dose. SCID mice were injected with an equimolar dose of the ADC via the tail vein. Blood was collected at the following time points: 15 minutes, 6 hours, 24 hours, 72 hours, 144 hours, 240 hours, and 336 hours after the first dose. Blood concentrations were determined by ELISA. Plates were coated with anti-hFc and incubated overnight at 4°C. After washing once with 300 μL of PBST buffer, the diluted test serum was added and incubated at room temperature for one hour. Each serum tube was assayed in two plates. One plate was washed three times with 300 μL of PBST buffer, and 100 μL of HRP-conjugated goat anti-human IgG Fc solution was added to each well and incubated at room temperature for one hour. After washing five times with PBST buffer, a colorimetric solution was added. After development, a stop buffer was added, and the OD450 value was read on a microplate reader. The PK parameters were calculated using a non-compartmental model using Phoenix software. The results are shown in Figure 15 and Table 22, which indicate that PR3178-9106 has superior pharmacokinetic characteristics to hSC200-9106.
[0248] Table 22. Pharmacokinetic parameters of ADC drugs in mice
[0249] The use and welfare of experimental animals in this disclosure were conducted in accordance with the guidelines of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). The animals were monitored daily for health and mortality. Routine examinations included observing the effects of test substances and drugs on the animals' daily behaviors, such as activity, weight, and physical appearance.
[0250] Although specific embodiments of the present disclosure have been described above, those skilled in the art will appreciate that these are merely illustrative and that various changes or modifications may be made to these embodiments without departing from the principles and essence of the present disclosure. Therefore, the scope of protection of the present disclosure is defined by the appended claims.
Claims
1. An anti-SEZ6 antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region (VH) or a heavy chain single domain (VHH), wherein the heavy chain variable region or the heavy chain single domain comprises: (1) heavy chain HCDR1, HCDR2, HCDR3 as shown in the amino acid sequences of SEQ ID NOs: 37, 38 and 39; or (2) heavy chain HCDR1, HCDR2, HCDR3 as shown in the amino acid sequences of SEQ ID NOs: 43, 44 and 45; or (3) heavy chain HCDR1, HCDR2, HCDR3 as shown in the amino acid sequences of SEQ ID NOs: 49, 50 and 51; or (4) heavy chain HCDR1, HCDR2, HCDR3 as shown in the amino acid sequences of SEQ ID NOs: 65, 66 and 67; or (5) Heavy chain HCDR1, HCDR2, and HCDR3 as shown in the amino acid sequences of SEQ ID NOs: 68, 69, and 70.
2. The anti-SEZ6 antibody or antigen-binding fragment thereof according to claim 1, comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the heavy chain variable region and the light chain variable region comprise: (1) heavy chain HCDR1, HCDR2, HCDR3 as shown in the amino acid sequences of SEQ ID NOs: 37, 38 and 39, and light chain LCDR1, LCDR2 and LCDR3 as shown in the amino acid sequences of SEQ ID NOs: 40, 41 and 42; or (2) heavy chain HCDR1, HCDR2, HCDR3 as shown in the amino acid sequences of SEQ ID NOs: 43, 44 and 45, and light chain LCDR1, LCDR2 and LCDR3 as shown in the amino acid sequences of SEQ ID NOs: 46, 47 and 48; or (3) heavy chain HCDR1, HCDR2, HCDR3 as shown in the amino acid sequences of SEQ ID NOs: 49, 50 and 51, and light chain LCDR1, LCDR2 and LCDR3 as shown in the amino acid sequences of SEQ ID NOs: 52, 53 and 54.
3. The anti-SEZ6 antibody or antigen-binding fragment thereof according to claim 1, wherein the heavy chain single domain comprises an amino acid sequence as shown in SEQ ID NO: 63, or a sequence having at least 85%, 90%, 95%, 99% homology thereto; or as shown in SEQ ID NO: 64, or a sequence having at least 85%, 90%, 95%, 99% homology thereto; Preferably, the heavy chain single domain comprises the amino acid sequence shown in SEQ ID NO:63, or as shown in SEQ ID NO:
64.
4. The anti-SERZ6 antibody or antigen-binding fragment thereof according to claim 1 or 2, comprising a heavy chain variable region and a light chain variable region, wherein: The heavy chain variable region comprises an amino acid sequence as shown in SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:35, or a sequence having at least 85%, 90%, 95%, 99% homology thereto; The light chain variable region comprises an amino acid sequence as shown in SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto.
5. The anti-SERZ6 antibody or antigen-binding fragment thereof according to claim 4, comprising a heavy chain variable region and a light chain variable region, wherein: (1) the heavy chain variable region comprises an amino acid sequence as shown in SEQ ID NO: 29, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto, and the light chain variable region comprises an amino acid sequence as shown in SEQ ID NO: 30, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto; or (2) the heavy chain variable region comprises an amino acid sequence as shown in SEQ ID NO: 31, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto, and the light chain variable region comprises an amino acid sequence as shown in SEQ ID NO: 32, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto; or (3) the heavy chain variable region comprises an amino acid sequence as shown in SEQ ID NO: 31, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto, and the light chain variable region comprises an amino acid sequence as shown in SEQ ID NO: 34, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto; or (4) the heavy chain variable region comprises an amino acid sequence as shown in SEQ ID NO: 35, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto, and the light chain variable region comprises an amino acid sequence as shown in SEQ ID NO: 36, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto; Preferably, (1) the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO: 29, and the light chain variable region comprises the amino acid sequence shown in SEQ ID NO: 30; or (2) the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO: 31, and the light chain variable region comprises the amino acid sequence shown in SEQ ID NO: 32; or (3) the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO: 31, and the light chain variable region comprises the amino acid sequence shown in SEQ ID NO: 34; or (4) The heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO: 35, and the light chain variable region comprises the amino acid sequence shown in SEQ ID NO:
36.
6. The anti-DLL3 antibody or antigen-binding fragment thereof according to any one of claims 1 to 5, wherein the antigen-binding fragment is selected from the group consisting of Fab, Fab', F(ab')2, single-chain antibody (scFv), single-domain antibody (sdAb), dimerized V region (diabody), disulfide-stabilized V region (dsFv) and an antigen-binding fragment of a peptide comprising CDRs.
7. The anti-SERZ6 antibody or antigen-binding fragment thereof according to any one of claims 1 to 6, comprising an antibody constant region; The heavy chain constant region is derived from human IgG1, IgG2, IgG3, IgG4 or a variant thereof; and / or the light chain constant region is derived from human IgG1, IgG2, IgG3, IgG4 or a variant thereof; The fixed region is derived from human antibody κ, λ chain or its variants; Preferably, the amino acid sequence of the heavy chain constant region is derived from human IgG1 or a variant thereof; and / or the light chain constant region is derived from human antibody κ chain or a variant thereof; More preferably, the heavy chain constant region comprises the amino acid sequence shown in SEQ ID NO:33, and / or the light chain constant region comprises the amino acid sequence shown in SEQ ID NO:
59.
8. The anti-DLL3 antibody or antigen-binding fragment thereof according to claim 7, comprising a heavy chain and a light chain, wherein: (1) the heavy chain comprises the amino acid sequence as shown in SEQ ID NO:55, or a sequence having at least 85%, 90%, 95%, 99% homology thereto, and the light chain comprises the amino acid sequence as shown in SEQ ID NO:56, or a sequence having at least 85%, 90%, 95%, 99% homology thereto; or (2) the heavy chain comprises the amino acid sequence as shown in SEQ ID NO:57, or a sequence having at least 85%, 90%, 95%, 99% homology thereto, and the light chain comprises the amino acid sequence as shown in SEQ ID NO:58, or a sequence having at least 85%, 90%, 95%, 99% homology thereto; or (3) the heavy chain comprises the amino acid sequence as shown in SEQ ID NO:57, or a sequence having at least 85%, 90%, 95%, 99% homology thereto, and the light chain comprises the amino acid sequence as shown in SEQ ID NO:60, or a sequence having at least 85%, 90%, 95%, 99% homology thereto; or (4) the heavy chain comprises the amino acid sequence as set forth in SEQ ID NO:61, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto, and the light chain comprises the amino acid sequence as set forth in SEQ ID NO:62, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto; Preferably, (1) the heavy chain comprises the amino acid sequence shown in SEQ ID NO:55, and the light chain comprises the amino acid sequence shown in SEQ ID NO:56; or (2) the heavy chain comprises the amino acid sequence shown in SEQ ID NO:57, and the light chain comprises the amino acid sequence shown in SEQ ID NO:58; or (3) the heavy chain comprises the amino acid sequence shown in SEQ ID NO:57, and the light chain comprises the amino acid sequence shown in SEQ ID NO:60; or (4) The heavy chain comprises the amino acid sequence shown in SEQ ID NO:61, and the light chain comprises the amino acid sequence shown in SEQ ID NO:
62.
9. The anti-DLL3 antibody or antigen-binding fragment thereof according to claim 3, which consists of a heavy chain, wherein: (1) the heavy chain comprises the amino acid sequence as shown in SEQ ID NO:71, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto; or (2) the heavy chain comprises the amino acid sequence as shown in SEQ ID NO:72, or a sequence having at least 85%, 90%, 95%, or 99% homology thereto; Preferably, (1) the heavy chain comprises the amino acid sequence shown in SEQ ID NO: 71; or (2) The heavy chain comprises the amino acid sequence shown in SEQ ID NO:
72.
10. An isolated nucleic acid encoding the anti-DLL3 antibody or antigen-binding fragment thereof according to any one of claims 1 to 9. A vector comprising the isolated nucleic acid of claim 10 . A host cell comprising the vector according to claim 11 .
13. A method for preparing an anti-SEZ6 antibody or an antigen-binding fragment thereof, comprising culturing the host cell of claim 12 under conditions suitable for expressing the anti-SEZ6 antibody or the antigen-binding fragment thereof.
14. An antibody-drug conjugate or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, comprising the anti-SEZ6 antibody or antigen-binding fragment thereof according to any one of claims 1 to 9 and a drug; wherein the drug is selected from the group consisting of: a cytotoxic agent, a radiolabel, a fluorophore, a chromophore, an imaging agent, an immunomodulator, an angiogenesis inhibitor, a cell proliferation inhibitor, a pro-apoptotic agent, a cell lytic enzyme, and any combination thereof; Preferably, the drug is selected from the group consisting of: DNA damaging agents, topoisomerase inhibitors, microtubule inhibitors, protein degraders, STING agonists, and any combination thereof.
15. The antibody-drug conjugate according to claim 14 or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a mixture thereof, which has a structure represented by general formula (I): Pc-(LY-Dr) n (I) in, Dr is the drug according to claim 14; Preferably, Dr is selected from the group consisting of camptothecin, auristatin, maytansinoid, vinca alkaloid, pyrrolobenzodiazepine (PBD), calicheamicin, duocarmycin, daunorubicin, doxorubicin, calicheamicin, anthramycin, neomycin, amatoxin, hemipteratin, eribulin, Tubulysin, and analogs or derivatives thereof; More preferably, Dr is selected from the group consisting of: Exatecan, MMAE, MMAF, MMAD, SN-38, DM1, DM4, pyrrolebenzodiazepine (PBD) dimer, and analogs or derivatives thereof; n is 1 to 10, n is a decimal or an integer, preferably n is 2 to 8, more preferably n is 3 to 5 or 4 to 8, further preferably n is 4 to 6, further preferably n is 5 to 6, and further preferably n is 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5 or 8; L and Y are joint units; Pc is the anti-SERZ6 antibody or an antigen-binding fragment thereof according to any one of claims 1 to 9.
16. The antibody-drug conjugate according to claim 14 or 15, or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a mixture thereof, having a structure represented by the general formula (Pc-LY-Dr), general formula (II), general formula (III), or general formula (IV): in: Y is selected from -O-(CR a R b ) m -CR 1 R 2 -C(O)-, -O-CR 1 R 2 -(CR a R b ) m -, -O-CR 1 R 2 -, -NH-(CR a R b ) m -CR 1 R 2 -C(O)- or -S-(CR a R b ) m -CR 1 R 2 -C(O)-; R a and R b are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen, an alkyl group, a haloalkyl group, a deuterated alkyl group, an alkoxy group, a hydroxyl group, an amino group, a cyano group, a nitro group, a hydroxyalkyl group, a cycloalkyl group or a heterocyclic group; Or, R a and R b Together with the carbon atom to which it is attached, it forms a cycloalkyl or heterocyclyl group; R 1 is selected from halogen, haloalkyl, deuterated alkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, heterocyclyl, aryl or heteroaryl; R 2 is selected from a hydrogen atom, a halogen, a haloalkyl group, a deuterated alkyl group, a cycloalkyl group, a cycloalkylalkyl group, an alkoxyalkyl group, a heterocyclyl group, an aryl group or a heteroaryl group; Or, R 1 and R 2 Together with the carbon atom to which it is attached, it forms a cycloalkyl or heterocyclyl group; Or, R a and R 2 Together with the carbon atom to which it is attached, it forms a cycloalkyl or heterocyclyl group; m is an integer from 0 to 4; n is 1 to 10, n is a decimal or an integer, preferably n is 2 to 8, more preferably n is 3 to 5 or 4 to 8, further preferably n is 4 to 6, further preferably n is 5 to 6, and further preferably, n 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5 or 8; L is the joint unit; Pc is the anti-SERZ6 antibody or an antigen-binding fragment thereof according to any one of claims 1 to 9.
17. The antibody-drug conjugate according to claim 16, or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a mixture thereof, in: Y is -O-(CR a R b ) m -CR 1 R 2 -C(O)-; R a and R b are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen or an alkyl group; R 1 is a halogenated alkyl or C 3-6 Cycloalkyl; R 2 is selected from a hydrogen atom, a haloalkyl group or a C 3-6 Cycloalkyl; Or, R 1 and R 2 Together with the carbon atom to which it is attached, it forms C 3-6 Cycloalkyl; m is 0 or 1.
18. The antibody-drug conjugate according to any one of claims 16 or 17, or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, wherein Y is selected from:
19. The antibody-drug conjugate according to any one of claims 16 to 18, or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a mixture thereof, wherein the O end of Y is connected to the linker unit L.
20. The antibody-drug conjugate according to any one of claims 16 to 19, or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a mixture thereof, wherein the linker unit -L- is -L 1 -L 2 -L 3 -L 4 -, L 1 for s 1 is an integer from 2 to 8; L 2 is a chemical bond; L 3 is a tetrapeptide residue; L 4 For-NR 5 (CR 6 R 7 )t-,R 5 , R 6 or R 7 are the same or different and are each independently a hydrogen atom or an alkyl group, and t is 1 or 2.
21. The antibody-drug conjugate according to any one of claims 16 to 19, or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a mixture thereof, wherein the linker unit -L- is -L 1 -L 2 -L 3 -L 4 -, L 1 for s 1 and 2 independently selected from integers from 0 to 8; preferably 1 is 2, s 2 is an integer from 2 to 8; more preferably, s 1 is 2, s 2 is 2, 3, 4, 5 or 6; L 2 is a chemical bond; L 3 is a tetrapeptide residue; L 4For-NR 5 (CR 6 R 7 )t-,R 5 , R 6 or R 7 are the same or different and are each independently a hydrogen atom or an alkyl group, and t is 1 or 2.
22. The antibody-drug conjugate according to any one of claims 16 to 21, or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a mixture thereof, wherein the linker unit -L-, wherein L 1 The end is connected to Pc, L 4 Connect the Y end.
23. The antibody-drug conjugate according to any one of claims 16 to 22, or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, wherein said L 3 The tetrapeptide residue is an amino acid residue formed by two or more amino acids selected from phenylalanine, glycine, valine, lysine, citrulline, serine, glutamic acid, and aspartic acid; preferably, the tetrapeptide residue is GGFG.
24. The antibody-drug conjugate according to any one of claims 16 to 23, or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a mixture thereof, wherein the antibody-drug conjugate is selected from: wherein Pc and n are as defined in claim 16.
25. The antibody-drug conjugate according to any one of claims 16 to 24, or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a mixture thereof, wherein the antibody-drug conjugate is selected from: wherein n is as defined in claim 16.
26. A kit comprising the anti-DLL3 antibody or antigen-binding fragment thereof according to any one of claims 1 to 9, or the antibody-drug conjugate or pharmaceutically acceptable salt or solvate thereof according to any one of claims 14 to 25, or a tautomer, mesoform, racemate, enantiomer, diastereomer, or a mixture thereof.
27. A pharmaceutical composition comprising the anti-DLL3 antibody or antigen-binding fragment thereof according to any one of claims 1 to 9, or the antibody-drug conjugate or pharmaceutically acceptable salt or solvate thereof according to any one of claims 14 to 25, or a tautomer, mesoform, racemate, enantiomer, diastereomer, or mixture thereof, and one or more pharmaceutically acceptable carriers.
28. Use of the anti-DLL3 antibody or antigen-binding fragment thereof according to any one of claims 1 to 9, or the antibody-drug conjugate or pharmaceutically acceptable salt or solvate thereof according to any one of claims 14 to 25, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or the pharmaceutical composition according to claim 27 in the preparation of a medicament for treating a disease or condition mediated by DLL3; Preferably, the SEZ6-mediated disease or disorder is a SEZ6-overexpressing cancer.
29. Use of the anti-SEZ6 antibody or antigen-binding fragment thereof according to any one of claims 1 to 9, or the antibody-drug conjugate or pharmaceutically acceptable salt or solvate thereof according to any one of claims 14 to 25, or its tautomer, mesoform, racemate, enantiomer, diastereomer, or mixture thereof, or the pharmaceutical composition according to claim 27 in the preparation of a medicament for treating or preventing tumors or cancer; Preferably, the tumor or cancer is selected from the group consisting of lung cancer, breast cancer, liver cancer, hepatobiliary cancer, pancreatic cancer, gastric cancer, gastrointestinal cancer, intestinal cancer, colon cancer, colorectal cancer, kidney cancer, clear cell renal cell carcinoma, ovarian cancer, endometrial cancer, cervical cancer, bladder cancer, prostate cancer, testicular cancer, skin cancer, melanoma, leukemia, lymphoma, bone cancer.
Citation Information
Patent Citations
Monomethylvaline compounds capable of conjugation to ligands
US20050238649A1
Novel sez6 modulators and methods of use
US20160287720A1
Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A
Anti sez6 antibodies and methods of use
WO2013126810A1
Anti-sez6 antibody drug conjugates and methods of use
WO2019232241A1
Cited By
Specific anti-SEZ6 target fully humanized antibody as well as preparation method and application thereof
CN120365421A
Pharmaceutical composition for treatment and / or prevention of cancer
CN123036312A
Pharmaceutical composition for treating and / or preventing cancer
WO2025206085A1
Sez6 antibody conjugates
WO2026149486A1
Pharmaceutical composition containing antibody-drug conjugate and medical use thereof
WO2026175380A1
